var title_f27_30_28128="Oral candidiasis - palate";
var content_f27_30_28128=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F61040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F61040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oral candidiasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    White papules and plaques are present on the palate and tongue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_30_28128=[""].join("\n");
var outline_f27_30_28128=null;
var title_f27_30_28129="Macromastia";
var content_f27_30_28129=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F86170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F86170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Macromastia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 230px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The breast: Examination and lesions. In: Emans, Laufer, Goldstein's Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_30_28129=[""].join("\n");
var outline_f27_30_28129=null;
var title_f27_30_28130="Taking uterosacral ligaments";
var content_f27_30_28130=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Clamping uterosacral ligaments during vaginal hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 295px; height: 400px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These ligaments are suture ligated after clamping.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_30_28130=[""].join("\n");
var outline_f27_30_28130=null;
var title_f27_30_28131="Retinoblastoma formation";
var content_f27_30_28131=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F73602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F73602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The genetics of retinoblastoma formation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 411px; height: 553px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The RB1 gene is located on human chromosome 13. In familial retinoblastoma, the fertilized egg carries one defective copy of the RB1 gene, and all retinal cells in this offspring carry only a single functional RB1 gene copy. If this surviving copy is eliminated in a retinal cell by a somatic mutation (the second hit of the Knudson two-hit hypothesis), the cell will lack RB1 gene function and will proliferate into a tumor. In sporadic retinoblastoma, the fertilized egg is genetically wild type at the RB1 locus. In the retina of this offspring, retinoblastoma development requires two successive somatic mutations striking both copies of the RB1 gene in the retinal precursor cells. Because only a single somatic mutation is needed to eliminate RB1 function in familial cases, multiple cells in both eyes are affected. In contrast, the two somatic mutations required in sporadic disease are unlikely to affect a single cell lineage, yielding at most one tumor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_30_28131=[""].join("\n");
var outline_f27_30_28131=null;
var title_f27_30_28132="Darifenacin: Patient drug information";
var content_f27_30_28132=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Darifenacin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43733?source=see_link\">",
"     see \"Darifenacin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F157055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Enablex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2950559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Enablex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat an overactive bladder.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701894",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to darifenacin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703507",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Trouble passing urine, glaucoma, very bad liver disease, myasthenia gravis, or slow clearing of the stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man with problems passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2858939",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid driving and doing other tasks or actions that call for you to be alert until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11202 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.167.4.114-B6D75EF485-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_30_28132=[""].join("\n");
var outline_f27_30_28132=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157055\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2950559\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014458\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014457\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014462\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014463\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014465\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014460\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014461\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014466\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014467\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43733?source=related_link\">",
"      Darifenacin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_30_28133="Treatment and prognosis of inclusion body myositis";
var content_f27_30_28133=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of inclusion body myositis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/30/28133/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/30/28133/contributors\">",
"     Marc L Miller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/30/28133/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/30/28133/contributors\">",
"     Ira N Targoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/30/28133/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/30/28133/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/30/28133/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/30/28133/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sporadic inclusion body myositis (IBM) is classified along with polymyositis and dermatomyositis as one of the idiopathic inflammatory myopathies. However, despite some histologic similarities, the clinicopathologic manifestations, treatment, and prognosis of IBM are clearly distinct from the other two disorders (",
"    <a class=\"graphic graphic_table graphicRef74076 \" href=\"UTD.htm?27/13/27867\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=see_link\">",
"     \"Initial treatment of dermatomyositis and polymyositis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13065?source=see_link\">",
"     \"Treatment of recurrent and resistant dermatomyositis and polymyositis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment and prognosis of inclusion body myositis will be reviewed here. The clinical manifestations and diagnosis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15735?source=see_link\">",
"     \"Clinical manifestations and diagnosis of inclusion body myositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to other inflammatory myopathies such as dermatomyositis and polymyositis, IBM is relatively resistant to standard immunosuppressive therapy, with muscle strength responding minimally, if at all, to glucocorticoids and other agents. It has been estimated that, in order to demonstrate a significant effect from treatment for IBM in a placebo-controlled study, 200 subjects would need to be enrolled in a six-month study or 100 in a year-long trial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28133/abstract/1\">",
"     1",
"    </a>",
"    ]. This estimate should be kept in mind when considering the data on efficacy of treatment presented below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids alone appear to have a limited role in patients with IBM [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28133/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. In the largest published series, muscle strength continued to deteriorate in all 25",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    -treated patients who were followed for at least two years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28133/abstract/2\">",
"     2",
"    </a>",
"    ]. Some other reports have noted a partial response to glucocorticoids with either mild improvement in or stabilization of muscle strength [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28133/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Serum creatine kinase levels often fall and may even normalize with glucocorticoid therapy; however, this biochemical response does not predict clinical benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28133/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is one apparent exception to the usually limited response to glucocorticoids. Patients with IBM associated with other connective tissue diseases (Sj&ouml;gren's syndrome, systemic lupus erythematosus, and the rash of dermatomyositis) may have a clinically important benefit from such therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28133/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Immunosuppressive treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , alone or in combination, have similarly shown, at best, minor benefit with no complete responses or major improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28133/abstract/3,4,8,9\">",
"     3,4,8,9",
"    </a>",
"    ]. Limited reported experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    has also not been encouraging [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28133/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with glucocorticoids, plasma creatine kinase (CK) levels often fall and may even normalize with immunosuppressive treatment; however, this biochemical response does not predict clinical benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28133/abstract/4,9\">",
"     4,9",
"    </a>",
"    ]. This observation was confirmed in a randomized study of 44 patients who received either weekly methotrexate or placebo for 48 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28133/abstract/9\">",
"     9",
"    </a>",
"    ]. Although the plasma CK decreased significantly in the methotrexate group, there was no significant difference in muscle strength between the two groups (decrease of 0.2 and 3.4 percent for methotrexate and placebo, respectively; 95% CI for the difference in strength between groups -2.5 to +9.1).",
"   </p>",
"   <p>",
"    Sex, age, and disease duration are not predictors of the response to therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Intravenous immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of intravenous immune globulin (IVIG) has been evaluated in three double-blind studies and two small open series [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28133/abstract/11-15\">",
"     11-15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A double-blind study randomly assigned 36 patients to either IVIG (monthly infusions for three months) or placebo infusions; all patients also received high-dose glucocorticoids [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28133/abstract/11\">",
"       11",
"      </a>",
"      ]. When compared with baseline, there were no significant differences in muscle strength during four months of observation. Follow-up biopsies revealed a greater reduction in the number of necrotic muscle fibers in those who received IVIG than in the placebo group, but this appeared to be of no clinical significance. The authors concluded that the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      and IVIG was ineffective in treating IBM.",
"     </li>",
"     <li>",
"      A double-blind, placebo-controlled crossover study involved 19 patients; no statistically significant improvement in overall muscle strength due to IVIG was observed. However, there was a trend toward improvement during IVIG treatment, and nine of the patients continued IVIG therapy independently after the study was concluded because of a sense of improved quality of life [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28133/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A double-blind, placebo-controlled crossover study of 11 patients did not suggest any benefit from IVIG in muscle strength, symptoms, or myographic test results [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28133/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an uncontrolled study, improvement in muscle strength and functional status was noted in three of four patients after the second monthly infusion [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28133/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A nonrandomized, open-label study included nine patients; no patient showed clinical improvement [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28133/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment with IVIG is not recommended because of its expenses and, at best, only very modest benefit. One exception may be the use of IVIG in the treatment of dysphagia. In one report, four patients with severe dysphagia due to upper esophageal dysfunction all recovered swallowing function after treatment with six to eight monthly infusions of IVIG [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28133/abstract/16\">",
"     16",
"    </a>",
"    ]. Further studies of IVIG may better define its role in this disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Approach to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The infrequent improvement in muscle strength in IBM has led some to consider the goal of therapy to be prevention of further deterioration in strength rather than improvement in strength [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28133/abstract/17\">",
"     17",
"    </a>",
"    ]. One problem is that IBM is often diagnosed years after the onset of symptoms. There may already be significant muscle damage by this time, preventing improvement in strength even if the disease process can be arrested.",
"   </p>",
"   <p>",
"    Another limitation is that ongoing inflammation may not be responsible for continued or progressive muscle weakness. As an example, serial muscle biopsies obtained before and after glucocorticoid treatment have demonstrated resolution of inflammation and a decrease in the number of muscle fibers invaded by inflammatory cells in patients with no clinical improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28133/abstract/18\">",
"     18",
"    </a>",
"    ]. Furthermore, the number of vacuolated fibers and the extent of amyloid deposition increased over time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15735?source=see_link\">",
"     \"Clinical manifestations and diagnosis of inclusion body myositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest the following empiric approach to treating patients with IBM [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28133/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initiate treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      at a dose of 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day.",
"     </li>",
"     <li>",
"      If there is continued decline in strength and function after approximately two to three months, consider the addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (starting at 7.5",
"      <span class=\"nowrap\">",
"       mg/week)",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      (1.5 to 2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) for a trial period of three to six months. There are no data to support the use of one of these agents rather than the other. The choice may be determined, in part, by other factors such as concern about hepatotoxicity with methotrexate in a patient with heavy alcohol use or with underlying liver disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link\">",
"       \"Use of methotrexate in the treatment of rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      All therapy should be discontinued if there is a continued decline in strength.",
"     </li>",
"     <li>",
"      If, on the other hand, muscle strength stabilizes or improves, we employ maintenance therapy with slowly tapering doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      continued",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      .",
"      <br/>",
"      <br/>",
"      This approach will provide treatment to those patients with IBM who are responders without exposing the majority who are non-responders to the toxicity of long-term glucocorticoid and immunosuppressive therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28133/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One other modality that may be helpful is cricopharyngeal myotomy in patients with dysphagia; these patients, however, remain at risk for aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28133/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients in whom the muscle biopsy is nondiagnostic but for whom there is still a clinical suspicion of IBM (eg, the patient is an older male), either an empiric trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or continued observation are reasonable depending on the severity of weakness. Lack of a response to prednisone favors the diagnosis of IBM, rather than of polymyositis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H383643\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to therapy is generally very poor. Patients who are untreated or who do not respond to treatment become gradually weaker over a period of years. The older the age at onset of the disease, the more rapid is the loss of strength and function. By 15 years, most patients require assistance with basic daily activities, and some become wheelchair bound or bedridden. IBM can be an indirect cause of death due to respiratory failure or infection, particularly respiratory tract infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15735?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of inclusion body myositis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/11/26804?source=see_link\">",
"       \"Patient information: Myositis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H382887\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inclusion body myositis (IBM) is relatively resistant to standard immunosuppressive therapy, with muscle strength responding minimally, if at all, to glucocorticoids and other agents. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An apparent exception to the usually limited response to glucocorticoids is that patients with IBM associated with other connective tissue diseases (eg, Sj&ouml;gren's syndrome, systemic lupus erythematosus, and cutaneous dermatomyositis) may have a clinically important benefit from such therapy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      have shown, at best, minor benefit, with no complete responses or major improvement. As with glucocorticoids, plasma creatine kinase levels often fall and may even normalize with immunosuppressive treatment; however, this biochemical response does not predict clinical benefit. Intravenous immune globulin (IVIG) has generally shown only modest benefit in a small number of patients but might be of benefit in some patients with dysphagia. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Immunosuppressive treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Intravenous immune globulin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We generally initiate therapy with a two- to three-month trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/kg/day).",
"      </span>",
"      In patients who exhibit a continued decline in strength and function, we add either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (starting at 7.5 mg once weekly) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      (target dose of 1.5 to 2.5",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      for a three- to six-month trial. Treatment is discontinued if strength continues to decline. In patients who respond to such therapy with stabilization or improvement in strength, we taper prednisone to the lowest dose needed to maintain such benefit and continue the other immunosuppressive. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Approach to treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients eventually require assistance with basic daily activities, typically after 10 to 15 years, and some become wheelchair bound or bedridden. Causes of death include respiratory failure due to IBM or respiratory tract infection. (See",
"      <a class=\"local\" href=\"#H383643\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28133/abstract/1\">",
"      Griggs RC. The current status of treatment for inclusion-body myositis. Neurology 2006; 66:S30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28133/abstract/2\">",
"      Lotz BP, Engel AG, Nishino H, et al. Inclusion body myositis. Observations in 40 patients. Brain 1989; 112 ( Pt 3):727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28133/abstract/3\">",
"      Sayers ME, Chou SM, Calabrese LH. Inclusion body myositis: analysis of 32 cases. J Rheumatol 1992; 19:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28133/abstract/4\">",
"      Leff RL, Miller FW, Hicks J, et al. The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy. Medicine (Baltimore) 1993; 72:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28133/abstract/5\">",
"      Joffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993; 94:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28133/abstract/6\">",
"      Yood RA, Smith TW. Inclusion body myositis and systemic lupus erythematosus. J Rheumatol 1985; 12:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28133/abstract/7\">",
"      Cohen MR, Sulaiman AR, Garancis JC, Wortmann RL. Clinical heterogeneity and treatment response in inclusion body myositis. Arthritis Rheum 1989; 32:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28133/abstract/8\">",
"      Beyenburg S, Zierz S, Jerusalem F. Inclusion body myositis: clinical and histopathological features of 36 patients. Clin Investig 1993; 71:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28133/abstract/9\">",
"      Badrising UA, Maat-Schieman ML, Ferrari MD, et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 2002; 51:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28133/abstract/10\">",
"      Hopkinson ND, Hunt C, Powell RJ, Lowe J. Inclusion body myositis: an underdiagnosed condition? Ann Rheum Dis 1993; 52:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28133/abstract/11\">",
"      Dalakas MC, Koffman B, Fujii M, et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001; 56:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28133/abstract/12\">",
"      Dalakas MC, Sonies B, Dambrosia J, et al. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997; 48:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28133/abstract/13\">",
"      Walter MC, Lochm&uuml;ller H, Toepfer M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 2000; 247:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28133/abstract/14\">",
"      Soueidan SA, Dalakas MC. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 1993; 43:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28133/abstract/15\">",
"      Amato AA, Barohn RJ, Jackson CE, et al. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology 1994; 44:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28133/abstract/16\">",
"      Cherin P, Pelletier S, Teixeira A, et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 2002; 58:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28133/abstract/17\">",
"      Wortmann RL. The dilemma of treating patients with inclusion body myositis. J Rheumatol 1992; 19:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28133/abstract/18\">",
"      Barohn RJ, Amato AA, Sahenk Z, et al. Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology 1995; 45:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28133/abstract/19\">",
"      Danon MJ, Friedman M. Inclusion body myositis associated with progressive dysphagia: treatment with cricopharyngeal myotomy. Can J Neurol Sci 1989; 16:436.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5164 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-77B11294E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_30_28133=[""].join("\n");
var outline_f27_30_28133=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H382887\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Immunosuppressive treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Intravenous immune globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Approach to treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H383643\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H382887\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5164\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5164|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/13/27867\" title=\"table 1\">",
"      IBM versus polymyositis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15735?source=related_link\">",
"      Clinical manifestations and diagnosis of inclusion body myositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=related_link\">",
"      Initial treatment of dermatomyositis and polymyositis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/11/26804?source=related_link\">",
"      Patient information: Myositis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13065?source=related_link\">",
"      Treatment of recurrent and resistant dermatomyositis and polymyositis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_30_28134="Use of an epinephrine autoinjector";
var content_f27_30_28134=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/30/28134/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/30/28134/contributors\">",
"     Scott H Sicherer, MD, FAAAAI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/30/28134/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/30/28134/contributors\">",
"     F Estelle R Simons, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/30/28134/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/30/28134/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/30/28134/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic reactions can be triggered by foods, medications, exercise, latex, insect stings, or unknown triggers, and can cause a sudden, potentially life-threatening allergic reaction called anaphylaxis. Epinephrine (also known as adrenaline) is a medicine that treats the symptoms of serious allergic reactions. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=see_link\">",
"     \"Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATIENT AND FAMILY EDUCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A person with allergies, as well as his or her family, close friends, teachers, and co-workers, should learn to use an epinephrine autoinjector before it is needed. Anaphylaxis is unpredictable, and while a person may have a mild reaction one time, a serious or even life-threatening reaction can occur the next time. A person suffering with anaphylaxis may panic and be unable to assist with their own injection. In addition, a quick response is necessary to prevent serious complications of anaphylaxis.",
"   </p>",
"   <p>",
"    An epinephrine autoinjector prescription should be filled immediately. Anyone who is at risk of anaphylaxis should keep at least one epinephrine autoinjector with them at all times. Most allergy specialists recommend having at least two doses of epinephrine available, and some prescribe more. The reason for this is that two doses of epinephrine may be needed to treat a more severe anaphylactic reaction.",
"   </p>",
"   <p>",
"    After filling the prescription,",
"    <span class=\"nowrap\">",
"     patients/caregivers",
"    </span>",
"    should practice using the autoinjector. Many manufacturers include a practice injector (that does not have a needle or actual medicine). A video (on the internet or DVD) showing how the autoinjector is used is available from some manufacturers and should be reviewed periodically.",
"   </p>",
"   <p>",
"    The autoinjector should always be available, including at school or work, when attending parties or traveling, during exercise, and while dining out. It should be kept in a place that can be easily located by others in an emergency and family and friends should be informed about where the injector is stored. It is also important to ensure that the injector is not expired, although an expired injector may be used if there is no alternative.",
"   </p>",
"   <p>",
"    Epinephrine should be stored at normal room temperature, away from extreme cold and heat. The epinephrine cartridge window should be examined periodically to ensure that the solution is colorless and contains no floating particles. Solutions that are discolored or contain particles should be replaced. Autoinjectors that have expired should be replaced even if the solution still looks clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SYMPTOMS OF ALLERGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic reaction can produce symptoms throughout the body. The symptoms of anaphylaxis are discussed in detail in a separate topic. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=see_link\">",
"     \"Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPINEPHRINE IS THE BEST TREATMENT FOR ANAPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epinephrine is the best treatment for anaphylaxis and it works best if it is given within the first few minutes of a severe allergic reaction. Epinephrine rapidly treats all of the most dangerous symptoms of anaphylaxis, including throat swelling, difficulty breathing, and low blood pressure. However, epinephrine is not a perfect treatment, so allergic triggers should be avoided.",
"   </p>",
"   <p>",
"    Other medicines that are used in the treatment of allergic reactions can help with some of the symptoms, but only epinephrine treats the entire reaction. Antihistamines (such as",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?24/60/25537?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    and others) help with itching and hives, and asthma inhalers (such as",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?39/50/40741?source=see_link\">",
"     albuterol",
"    </a>",
"    ) can help with coughing and wheezing, but these medications do not treat the dangerous symptoms of throat swelling and low blood pressure. In addition, antihistamines taken by mouth are too slow-acting to be effective in a rapidly-developing episode of anaphylaxis. In contrast, injected epinephrine works within a few minutes.",
"   </p>",
"   <p>",
"    In short, antihistamines and asthma inhalers are useful in the treatment of anaphylaxis, but they are NOT substitutes for epinephrine. There is no substitute for epinephrine in anaphylaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     WHEN TO USE AN EPINEPHRINE AUTOINJECTOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;A person who is having an allergic reaction should use their epinephrine autoinjector",
"    <strong>",
"     immediately",
"    </strong>",
"    if they:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Are having trouble breathing",
"     </li>",
"     <li>",
"      Feel tightness in the throat",
"     </li>",
"     <li>",
"      Feel lightheaded or think they might pass out",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If treating a child with an allergic reaction,",
"    <strong>",
"     also",
"    </strong>",
"    use the autoinjector if the child:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is not responding, seems groggy, or passes out during an allergic reaction.",
"     </li>",
"     <li>",
"      Has food allergies and is vomiting repeatedly shortly after eating, especially if these symptoms are accompanied by flushing or hives.",
"     </li>",
"     <li>",
"      Is coughing repeatedly during an allergic reaction.",
"     </li>",
"     <li>",
"      Had previous anaphylaxis and develops widespread hives after possibly eating a trigger food.",
"     </li>",
"     <li>",
"      Has definitely eaten a trigger food that previously caused very severe anaphylaxis. In this case, use the autoinjector before symptoms appear.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HOW TO USE AN EPINEPHRINE AUTOINJECTOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient and a family member should review instructions provided with the autoinjector each time a refill is obtained in case there are changes. Instructions may differ from one autoinjector to another.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Epipen or Epipen Jr.",
"    </span>",
"    &nbsp;&mdash;&nbsp;These epinephrine autoinjectors contain one dose per injector. They are available in two different doses, one intended for older children and adults, and the other for use in young children.",
"   </p>",
"   <p>",
"    Stay with other people if possible. There is no need to undress, because the injector works through clothing. However, when possible, lift the edge of a skirt or lower pants to avoid hitting a buckle, zipper, or contents of the pockets.",
"   </p>",
"   <p>",
"    &nbsp;1. &nbsp;Flip open the cap and remove the pen from its carrier tube.",
"   </p>",
"   <p>",
"    &nbsp;2. &nbsp;Hold the injector in your dominant hand, making a fist. Keep fingers away from both ends to avoid sticking them. The end with the orange tip contains the needle and should be facing down. Use your other hand to pull off the blue safety release.",
"   </p>",
"   <p>",
"    &nbsp;3. &nbsp;Hold the orange tip near the outer thigh. Swing and",
"    <strong>",
"     firmly push",
"    </strong>",
"    against the outer thigh until it clicks so that the unit is perpendicular (90 degree angle) to the thigh.",
"    <strong>",
"     Hold in place for 10 seconds",
"    </strong>",
"    to allow all the medicine to be injected (",
"    <a class=\"graphic graphic_picture graphicRef75436 \" href=\"UTD.htm?11/44/11975\">",
"     picture 1",
"    </a>",
"    ). The cartridge window will become obscured.",
"   </p>",
"   <p>",
"    &nbsp;4. &nbsp;Remove the pen from the thigh. The orange needle cover will extend to automatically cover the needle.",
"   </p>",
"   <p>",
"    5. &nbsp;Massage the injected area for 10 seconds.",
"   </p>",
"   <p>",
"    &nbsp;6. &nbsp;Call 911 and get to the nearest emergency department immediately (patients should",
"    <strong>",
"     not",
"    </strong>",
"    drive themselves). Allergic reactions sometimes come back.",
"   </p>",
"   <p>",
"    &nbsp;7. &nbsp;Take the used autoinjector with you to the hospital emergency room so that it can be disposed of safely.",
"   </p>",
"   <p>",
"    The Epipen is available in packages of two, in case a second dose is needed. Large-sized adults may need to repeat the dose. A second dose may also be needed if symptoms are not improving or getting worse after about five minutes, or if symptoms come back before reaching the emergency department.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19098418\">",
"    <span class=\"h2\">",
"     Auvi-Q",
"    </span>",
"    &nbsp;&mdash;&nbsp;These epinephrine autoinjectors contain one dose per injector. They are rectangular, about the size of a cellular phone, and play a recording that explains each step in the self-injecting process. They are available in two different doses, one intended for older children and adults, and the other for use in young children.",
"   </p>",
"   <p>",
"    Stay with other people if possible. There is no need to undress, because the injector works through clothing. However, when possible, lift the edge of a skirt or lower pants to avoid hitting a buckle, zipper, or contents of the pockets.",
"   </p>",
"   <p>",
"    1. &nbsp;Pull downwards to remove the blue or red case.",
"   </p>",
"   <p>",
"    &nbsp;2. &nbsp;Pull off the red safety guard. This will reveal a black end which contains a needle inside. Do not place your finger or hand over the black end.",
"   </p>",
"   <p>",
"    &nbsp;3. &nbsp;Place the black end against the upper, outer thigh, and press down hard until the autoinjector fires (you will hear a click and a hiss).",
"    <strong>",
"     Hold in place for 5 seconds",
"    </strong>",
"    to allow all the medicine to be injected.",
"   </p>",
"   <p>",
"    &nbsp;4. &nbsp;Remove the injector.",
"   </p>",
"   <p>",
"    5. &nbsp;Call 911 and get to the nearest emergency department immediately. (Patients should",
"    <strong>",
"     not",
"    </strong>",
"    drive themselves). Allergic reactions sometimes come back.",
"   </p>",
"   <p>",
"    6. &nbsp;Take the used injector to the hospital for disposal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9852316\">",
"    <span class=\"h2\">",
"     Other devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two other autoinjectors, Adrenaclick and Twinject, are currently unavailable in the United States, although they may be reintroduced at a later date.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9852352\">",
"    <span class=\"h3\">",
"     Adrenaclick",
"    </span>",
"    &nbsp;&mdash;&nbsp;This autoinjector contains one dose of epinephrine. It is available in two different strengths, one intended for use in children and the other, for use in adolescents and adults. Adrenaclick is not currently available in the United States, although it may be again in the future.",
"   </p>",
"   <p>",
"    Stay with other people if possible. There is no need to undress, because the injector works through clothing. However, when possible, lift the edge of a skirt or lower pants to avoid hitting a buckle, zipper, or contents of the pockets.",
"   </p>",
"   <p>",
"    &nbsp;1. &nbsp;Remove the injector from its gray case.",
"   </p>",
"   <p>",
"    &nbsp;2. &nbsp;Pull off the gray cap, labeled \"1\". This will reveal a red tip, which contains a needle inside. Do not place your finger or hand over the red tip.",
"   </p>",
"   <p>",
"    &nbsp;3. &nbsp;Pull off the gray cap, labeled \"2\".",
"   </p>",
"   <p>",
"    &nbsp;4. &nbsp;Form a fist around the autoinjector with the red tip pointing down.",
"   </p>",
"   <p>",
"    &nbsp;5. &nbsp;Place the red tip against the upper, outer thigh, and press down hard until the autoinjector fires (",
"    <a class=\"graphic graphic_picture graphicRef75436 \" href=\"UTD.htm?11/44/11975\">",
"     picture 1",
"    </a>",
"    ).",
"    <strong>",
"     Hold in place for 10 seconds",
"    </strong>",
"    to allow all the medicine to be injected.",
"   </p>",
"   <p>",
"    &nbsp;6. &nbsp;Remove the injector and check the red cap. If the needle is visible, epinephrine was given. If the needle is not present, repeat steps 4 through 5 again.",
"   </p>",
"   <p>",
"    &nbsp;7. &nbsp;Massage the injected area for 10 seconds.",
"   </p>",
"   <p>",
"    &nbsp;8. &nbsp;Call 911 and get to the nearest emergency department immediately. (Patients should",
"    <strong>",
"     not",
"    </strong>",
"    drive themselves). Allergic reactions sometimes come back.",
"   </p>",
"   <p>",
"    &nbsp;9. &nbsp;Place the used injector back into the carrying case needle end first, and close the case by putting the light gray case top over the non-needle end and close the case. Take the case to the hospital for disposal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9852359\">",
"    <span class=\"h3\">",
"     Twinject",
"    </span>",
"    &nbsp;&mdash;&nbsp;This autoinjector contains two doses in one device. It is available in two different strengths, one intended for use in children and the other, for use in adolescents and adults. Twinject is not currently available in the United States, although it may be again in the future.",
"   </p>",
"   <p>",
"    Stay with other people if possible. There is no need to undress, because the injector works through clothing. However, when possible, lift the edge of a skirt or lower pants to avoid hitting a buckle, zipper, or contents of the pockets.",
"   </p>",
"   <p>",
"    &nbsp;1. &nbsp;Remove the injector from its case.",
"   </p>",
"   <p>",
"    &nbsp;2. &nbsp;Pull off the green cap, labeled \"1\". This will reveal a red tip, which contains a needle inside. Do not place your finger or hand over the red tip.",
"   </p>",
"   <p>",
"    &nbsp;3. &nbsp;Pull off the green cap, labeled \"2\".",
"   </p>",
"   <p>",
"    &nbsp;4. &nbsp;Form a fist around the autoinjector with the red tip pointing down.",
"   </p>",
"   <p>",
"    &nbsp;5. &nbsp;Place the red tip against the upper, outer thigh, and press down hard until the autoinjector fires (",
"    <a class=\"graphic graphic_picture graphicRef75436 \" href=\"UTD.htm?11/44/11975\">",
"     picture 1",
"    </a>",
"    ).",
"    <strong>",
"     Hold in place for 10 seconds",
"    </strong>",
"    to allow all the medicine to be injected.",
"   </p>",
"   <p>",
"    &nbsp;6. &nbsp;Remove the injector and check the red cap. If the needle is visible, epinephrine was given. If the needle is not present, repeat steps 4 through 5 again.",
"   </p>",
"   <p>",
"    &nbsp;7. &nbsp;Massage the injected area for 10 seconds.",
"   </p>",
"   <p>",
"    &nbsp;8. &nbsp;Call 911 and get to the nearest emergency department immediately. (Patients should",
"    <strong>",
"     not",
"    </strong>",
"    drive themselves). Allergic reactions sometimes come back.",
"   </p>",
"   <p>",
"    The Twinject contains a second dose inside the cartridge. A second dose may be needed if symptoms are not improving or getting worse after about five minutes, or if symptoms come back before reaching the emergency department. Studies have shown that one in three patients will need a second dose.",
"   </p>",
"   <p>",
"    In case a second dose is needed, remove the inside injector:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unscrew and remove the red rounded tip, taking care to avoid the needle.",
"     </li>",
"     <li>",
"      Pull the blue syringe out of the barrel.",
"     </li>",
"     <li>",
"      Slide the yellow collar off the plunger. Do not pull up on the plunger.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To use the second dose:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Press the injector firmly into your thigh muscle; push the plunger all the way down to inject the medicine.",
"     </li>",
"     <li>",
"      Remove the injector.",
"     </li>",
"     <li>",
"      Massage the injected area for 10 seconds.",
"     </li>",
"     <li>",
"      Place the used syringe and needle back into the case and take it to the hospital.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the second dose was not needed, the",
"    <span class=\"nowrap\">",
"     syringe/needle",
"    </span>",
"    can be stored in the case for disposal at the hospital. The second dose CANNOT be saved for use another day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Immediately after using the autoinjector",
"    </span>",
"    &nbsp;&mdash;&nbsp;After using an autoinjector, it is important to immediately seek care in an emergency department. The reaction may initially improve, but then come back. When possible, ask someone else to call for help. If alone, treat with the autoinjector first and then call or walk for help.",
"   </p>",
"   <p>",
"    If the person experiencing anaphylaxis begins to feel weak or dizzy, have them lie down and elevate the knees or feet. If they feel faint or have fainted, leave them in the lying down position. NEVER prop them up because this can prevent blood from reaching the heart and brain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Side effects of epinephrine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of epinephrine are FAR GREATER than the risk of side effects. However, epinephrine can cause short-lived side effects in some patients. The most common side effects include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Heart &mdash; Fast",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pounding heartbeat, fleeting chest pain",
"     </li>",
"     <li>",
"      Nervous system &mdash; Nervousness, trembling, feeling cold, anxiety, headache, dizziness",
"     </li>",
"     <li>",
"      Digestive system &mdash; Nausea, dry throat",
"     </li>",
"     <li>",
"      Lungs &mdash; Fleeting shortness of breath",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Injector disposal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The injector should not be thrown away in the normal trash. Instead, patients should take their used or expired injector (inside the case) to a hospital or healthcare provider for proper disposal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;People have varying responses to a severe allergic reaction. Some people have symptoms that will resolve rapidly and completely with treatment. These people may feel tired, but otherwise normal afterwards. Other people have symptoms that take longer to resolve. For most people, facial swelling and asthma symptoms resolve completely after 24 to 48 hours.",
"   </p>",
"   <p>",
"    Some people experience a second reaction after the initial allergic reaction, although this is not common. Second reactions can occur hours to days later, although most second reactions happen within eight hours. For this reason, it is important to stay at the emergency department for several hours of observation after a reaction.",
"   </p>",
"   <p>",
"    A healthcare provider may prescribe additional medications for treatment after a reaction, such as antihistamines or oral glucocorticoids (eg,",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?27/36/28230?source=see_link\">",
"     prednisone",
"    </a>",
"    ). It is possible (but not proven) that these medications can help to prevent a second reaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     WHERE TO GET MORE INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"   </p>",
"   <p>",
"    This article will be updated as needed on our web site (",
"    <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"     www.uptodate.com/patients",
"    </a>",
"    ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1804444648\">",
"    <span class=\"h2\">",
"     Patient level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3357831\">",
"    <span class=\"h3\">",
"     The Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?28/57/29586?source=see_link\">",
"     Patient information: Epinephrine auto-injectors (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?32/30/33250?source=see_link\">",
"     Patient information: Anaphylaxis (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?1/31/1523?source=see_link\">",
"     Patient information: Angioedema (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?24/42/25250?source=see_link\">",
"     Patient information: Insect allergy (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?41/24/42370?source=see_link\">",
"     Patient information: Allergy skin testing (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?17/35/17971?source=see_link\">",
"     Patient information: Peanut allergy (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?23/3/23603?source=see_link\">",
"     Patient information: Drug allergy (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?41/5/42066?source=see_link\">",
"     Patient information: Allergy shots (The Basics)",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3357857\">",
"    <span class=\"h3\">",
"     Beyond the Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=see_link\">",
"     Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"    </a>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Professional level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     Anaphylaxis: Rapid recognition and treatment",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/1/12313?source=see_link\">",
"     Bee, yellow jacket, wasp, and other Hymenoptera stings: Reaction types and acute management",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=see_link\">",
"     Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=see_link\">",
"     Clinical manifestations of food allergy: An overview",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14824?source=see_link\">",
"     Diagnosis of Hymenoptera venom allergy",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=see_link\">",
"     Diagnostic evaluation of food allergy",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=see_link\">",
"     Drug eruptions",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1241?source=see_link\">",
"     Fatal anaphylaxis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3705?source=see_link\">",
"     Food allergy in schools and camps",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38920?source=see_link\">",
"     Food-induced anaphylaxis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26904?source=see_link\">",
"     History and physical examination in the patient with possible food allergy",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40809?source=see_link\">",
"     Laboratory tests to support the clinical diagnosis of anaphylaxis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18778?source=see_link\">",
"     Pathophysiology of anaphylaxis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23832?source=see_link\">",
"     Prescribing epinephrine for anaphylaxis self-treatment",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33657?source=see_link\">",
"     Hereditary angioedema: Treatment of acute attacks",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33625?source=see_link\">",
"     Unique aspects of anaphylaxis in infants",
"    </a>",
"    <br/>",
"   </p>",
"   <p>",
"    The following organizations also provide reliable health information.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Food Allergy and Anaphylaxis Network",
"      <br/>",
"      <br/>",
"      (",
"      <a class=\"external\" href=\"file://www.foodallergy.org/\">",
"       www.foodallergy.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      American Academy of Allergy, Asthma, and Immunology",
"      <br/>",
"      <br/>",
"      (",
"      <a class=\"external\" href=\"file://www.aaaai.org\">",
"       www.aaaai.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Anaphylaxis Foundation and Anaphylaxis Network of Canada",
"      <br/>",
"      <br/>",
"      (",
"      <a class=\"external\" href=\"file://www.anaphylaxis.org/\">",
"       www.anaphylaxis.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The Anaphylaxis Campaign",
"      <br/>",
"      <br/>",
"      (",
"      <a class=\"external\" href=\"file://www.anaphylaxis.org.uk/\">",
"       www.anaphylaxis.org.uk",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28134/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28134/abstract/1\">",
"      Sampson HA, Mu&ntilde;oz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28134/abstract/2\">",
"      Sampson HA, Mu&ntilde;oz-Furlong A, Bock SA, et al. Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol 2005; 115:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28134/abstract/3\">",
"      Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol 2005; 115:S483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28134/abstract/4\">",
"      Chamberlain D. Emergency medical treatment of anaphylactic reactions. Project Team of the Resuscitation Council (UK). J Accid Emerg Med 1999; 16:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28134/abstract/5\">",
"      Golden DB. Patterns of anaphylaxis: acute and late phase features of allergic reactions. Novartis Found Symp 2004; 257:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28134/abstract/6\">",
"      Pumphrey R. Anaphylaxis: can we tell who is at risk of a fatal reaction? Curr Opin Allergy Clin Immunol 2004; 4:285.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 365 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.181.191-2D925142A9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_30_28134=[""].join("\n");
var outline_f27_30_28134=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATIENT AND FAMILY EDUCATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SYMPTOMS OF ALLERGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPINEPHRINE IS THE BEST TREATMENT FOR ANAPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      WHEN TO USE AN EPINEPHRINE AUTOINJECTOR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HOW TO USE AN EPINEPHRINE AUTOINJECTOR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Epipen or Epipen Jr.",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19098418\">",
"      Auvi-Q",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9852316\">",
"      Other devices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9852352\">",
"      - Adrenaclick",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9852359\">",
"      - Twinject",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Immediately after using the autoinjector",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Side effects of epinephrine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Injector disposal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      WHERE TO GET MORE INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1804444648\">",
"      Patient level information",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3357831\">",
"      - The Basics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3357857\">",
"      - Beyond the Basics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Professional level information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/365\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PI/365|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/44/11975\" title=\"picture 1\">",
"      Epinephrine auto-inject PI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/1/12313?source=related_link\">",
"      Bee, yellow jacket, wasp, and other Hymenoptera stings: Reaction types and acute management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=related_link\">",
"      Clinical manifestations of food allergy: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14824?source=related_link\">",
"      Diagnosis of Hymenoptera venom allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=related_link\">",
"      Diagnostic evaluation of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1241?source=related_link\">",
"      Fatal anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3705?source=related_link\">",
"      Food allergy in schools and camps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38920?source=related_link\">",
"      Food-induced anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=related_link\">",
"      Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33657?source=related_link\">",
"      Hereditary angioedema: Treatment of acute attacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26904?source=related_link\">",
"      History and physical examination in the patient with possible food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40809?source=related_link\">",
"      Laboratory tests to support the clinical diagnosis of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18778?source=related_link\">",
"      Pathophysiology of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/5/42066?source=related_link\">",
"      Patient information: Allergy shots (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/24/42370?source=related_link\">",
"      Patient information: Allergy skin testing (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/30/33250?source=related_link\">",
"      Patient information: Anaphylaxis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=related_link\">",
"      Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/31/1523?source=related_link\">",
"      Patient information: Angioedema (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/3/23603?source=related_link\">",
"      Patient information: Drug allergy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/57/29586?source=related_link\">",
"      Patient information: Epinephrine auto-injectors (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/42/25250?source=related_link\">",
"      Patient information: Insect allergy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/35/17971?source=related_link\">",
"      Patient information: Peanut allergy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23832?source=related_link\">",
"      Prescribing epinephrine for anaphylaxis self-treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33625?source=related_link\">",
"      Unique aspects of anaphylaxis in infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_30_28135="Bacillus Calmette-Guerin (BCG) vaccine: Drug information";
var content_f27_30_28135=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bacillus Calmette-Guerin (BCG) vaccine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/39/40564?source=see_link\">",
"    see \"Bacillus Calmette-Guerin (BCG) vaccine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F139164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      BCG Vaccine;",
"     </li>",
"     <li>",
"      TheraCys&reg;;",
"     </li>",
"     <li>",
"      TICE&reg; BCG",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F139165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      BCG Vaccine;",
"     </li>",
"     <li>",
"      ImmuCyst&reg;;",
"     </li>",
"     <li>",
"      Oncotice&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F139177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Biological Response Modulator;",
"     </li>",
"     <li>",
"      Vaccine, Live (Bacterial)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F139166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Immunization against tuberculosis:",
"     </b>",
"     Percutaneous: 0.2-0.3 mL (full strength dilution); conduct postvaccinal tuberculin test (5 TU of PPD) in 2-3 months; if test is negative, repeat vaccination.",
"     <b>",
"      Note:",
"     </b>",
"     Initial lesion usually appears after 10-14 days consisting of small, red papule at injection site and reaches maximum diameter of 3 mm in 4-6 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Immunotherapy for bladder cancer:",
"     </b>",
"     Intravesicular:",
"     <b>",
"      Note:",
"     </b>",
"     Treatment should begin 7-14 days after biopsy or TUR. The contents of one vial is used for each dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     TheraCys&reg;: One dose instilled into bladder (retain for 2 hours) once weekly for 6 weeks followed by 1 treatment at 3, 6, 12, 18, and 24 months after initial treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TICE&reg; BCG: One dose instilled into the bladder (retain for 2 hours) once weekly for 6 weeks (may repeat cycle 1 time) followed by approximately once monthly for at least 6-12 months",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F139173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Immunization against tuberculosis:",
"     </b>",
"     Percutaneous:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &lt;1 month: 0.2-0.3 mL (half-strength dilution). Administer tuberculin test (5 TU) after 2-3 months; repeat vaccination after 1 year of age for negative tuberculin test if indications persist.",
"     <b>",
"      Note:",
"     </b>",
"     Initial lesion usually appears after 10-14 days consisting of small, red papule at injection site and reaches maximum diameter of 3 mm in 4-6 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &gt;1 month: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2558433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15673275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15673276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F139151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, intravesical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TICE&reg; BCG: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, intravesical [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TheraCys&reg;: 81 mg [contains natural rubber/natural latex in packaging; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TheraCys&reg;: 81 mg [contains natural rubber/natural latex in packaging, polysorbate 80 (in diluent); supplied with diluent] [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, percutaneous:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BCG Vaccine: 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F139137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F139154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should only be given intravesicularly (bladder irrigation) or percutaneously;",
"     <b>",
"      do not administer I.V., SubQ, I.M., or intradermally",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intravesicular: Empty or drain bladder. Instill BCG vaccine; retain for as long as possible, up to 2 hours. Patient should lie prone, rotating positions every 15 minutes to maximize bladder surface exposure. Following bladder instillation, patients should be instructed to void in a seated position in order to avoid the splashing of urine; burning may occur with the first void following therapy. Prior to flushing, disinfect the urine for 15 minutes with an equal amount of household bleach (this should be done for the first 6 hours after therapy). After administration, patients should drink plenty of water in order to flush the bladder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Percutaneous: Apply vaccine with syringe and needle by dropping onto 1-2 inch area of horizontally positioned surface of cleansed, dry site (deltoid region of arm preferred); pulling skin tight, puncture skin with multiple puncture device centered over the vaccine; apply pressure for 5 seconds; spread vaccine evenly over puncture area. Apply loose covering and keep dry for 24 hours.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Simultaneous administration of vaccines helps ensure the patients will be fully vaccinated by the appropriate age. Simultaneous administration of vaccines is defined as administering &gt;1 vaccine on the same day at different anatomic sites. Separate vaccines should not be combined in the same syringe unless indicated by product specific labeling. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible. Adolescents and adults should be vaccinated while seated or lying down. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F139152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG intravesical: Treatment and prophylaxis of carcinoma",
"     <i>",
"      in situ",
"     </i>",
"     of the bladder; prophylaxis of primary or recurrent superficial or minimally invasive papillary tumors following transurethral resection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG vaccine: Immunization against",
"     <i>",
"      Mycobacterium tuberculosis",
"     </i>",
"     in persons not previously infected and who are at high risk for exposure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     BCG vaccine is not routinely administered for the prevention of",
"     <i>",
"      M. tuberculosis",
"     </i>",
"     in the United States. The Advisory Committee on Immunization Practices (ACIP) recommends vaccination be considered for the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Children with a negative tuberculin skin test who are continually exposed to (and cannot be separated from) adults who are untreated or ineffectively treated for TB disease when the child cannot be given long-term treatment for infection",
"     <b>",
"      or",
"     </b>",
"     if the adult has TB caused by strains resistant to isoniazid and rifampin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Healthcare workers with a high percentage of patients with",
"     <i>",
"      M. tuberculosis",
"     </i>",
"     strains resistant to both isoniazid and rifampin, if there is ongoing transmission of the resistant strains and subsequent infection is likely, or if comprehensive infection-control precautions have not been successful. In addition, healthcare workers should be counseled on the risks and benefits of vaccination and treatment of  latent TB infection",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3401584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       BCG (intravesical) may be confused with BCG for immunization",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F139175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Following vaccination, all serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     Adverse events following intravesicular administration should be reported to MEDWATCH (800-FDA-1088 or",
"     <a href=\"file://www.fda.gov/Safety/MedWatch/default.htm\" target=\"_blank\">",
"      www.fda.gov/medwatch",
"     </a>",
"     ) or the manufacturer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Adverse reactions associated with",
"     <b>",
"      intravesicular administration",
"     </b>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Malaise (7% to 40%), fever (17% to 38%), chills (9% to 34%), pain (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (3% to 16%), anorexia/weight loss (2% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Dysuria (52% to 60%), bladder irritation (50%), urinary frequency (40% to 50%), hematuria (26% to 39%), cystitis (6% to 30%), urinary urgency (6% to 18%), urinary tract infection (2% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematological: Anemia (&lt;21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (24% to 33%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (6%), abdominal pain (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Genital pain (10%), hemorrhagic cystitis (9%), bladder cramps/pain (6% to 8%), urinary incontinence (2% to 6%), contracted bladder (5%), nocturia (5%), urinary debris (2%), genital inflammation/abscess (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematological: Leukopenia (&lt;6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia/myalgia (3% to 7%), cramps/pain (4%), rigors (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Renal toxicity (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pulmonary infection (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (&lt;1% to 5%), diaphoresis (3%), allergy (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abscesses, BCG infection, BCG reaction, blood urea nitrogen increased, coagulopathy, conjunctivitis, creatinine increased, disseminated sepsis, epididymitis, erythema nodosum leprosum, flank pain, granulomatous chorioretinitis, hepatic granuloma, hepatitis, interstitial lung disease, iritis, keratitis,",
"     <i>",
"      M. bovis",
"     </i>",
"     infection (lung, liver, bone, bone marrow, kidney, lymph nodes, prostate, eye, peritoneum), myoglobinuria, nephritis, orchitis, pneumonitis, prostatitis, pyelonephritis, renal failure, Reiter's syndrome, skin ulceration, thrombocytopenia, urethritis, urinary obstruction, urinary retention, uveitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Adverse reactions associated with",
"     <b>",
"      BCG vaccination",
"     </b>",
"     : Axillary lymphadenopathy, cervical lymphadenopathy, disseminated BCG infection (BCG osteomyelitis; may occur from 4 months to 2 years after vaccination), local reactions (induration, itching, lesions, lymphadenitis, pustule, tenderness, ulceration). Local reactions may persist for up to 3 months; more severe manifestations may occur up to 5 months after vaccination and persist for several weeks.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F139156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immunosuppressed patients or persons with congenital or acquired immune deficiencies (eg, HIV infection, leukemia, lymphoma, cancer therapy, immunosuppressive therapy such as corticosteroids); active tuberculosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG intravesical additional contraindications: Febrile illness, urinary tract infection, or gross hematuria; current symptoms or previous history of a systemic BCG reaction; recent (&lt;7-14 days) biopsy, transurethral resection (TUR), or traumatic catheterization",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG vaccine additional contraindications: Prior hypersensitivity to the vaccine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F139141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1:1000) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; BCG reaction: A systemic granulomatous illness occurring following exposure to BCG is referred to as a systemic BCG reaction when any of the following are present without another detectable etiology: fever &ge;39.5&deg;C for &ge;12 hours or &ge; 38.5&deg;C for &ge;48 hours; pneumonitis; hepatitis; organ dysfunction outside of the GU tract with granulomatous inflammation; clinical signs of sepsis. A systemic BCG reaction is more likely to occur with intravesical administration &lt;7 days after a biopsy, transurethral resection (TUR), or traumatic catheterization. Systemic symptoms may also occur following BCG vaccination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bladder irritation: Intravesical BCG may cause symptoms of bladder irritability which usually begin 4-6 hours after instillation and may last 24-72 hours; symptoms may increase in severity following each instillation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Disseminated infections:",
"     <b>",
"      [U.S. Boxed Warning]: May cause disseminated (including fatal) infections following intravesical administration.",
"     </b>",
"     Instillation to actively bleeding mucosa may promote systemic BCG infection or sepsis; postpone treatment for &ge;1 week following TUR, biopsy, traumatic catheterization, or gross hematuria. Do not use in patients with concurrent infections. Use caution in patients with aneurysms and prosthetic devices; ectopic BCG infection may occur at these sites. If signs and symptoms of a systemic BCG infection occur, permanently discontinue BCG treatment and begin therapy with &ge;2 antimycobacterial agents while conducting a diagnostic evaluation. Infection from vaccine is not sensitive to pyrazinamide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV: Should be administered with caution to persons in groups at high risk for HIV. Use is contraindicated in HIV-infected persons, and  HIV-infected persons thought to be infected with",
"     <i>",
"      Mycobacterium tuberculosis",
"     </i>",
"     should be strongly recommended for tuberculosis preventive therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunocompromised: Intravesical products should not be handled by persons with an immunodeficiency. All products are contraindicated for use in immunocompromised patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Small bladder capacity: Intravesical instillation may be associated with increased risk of severe local reactions in the presence of small bladder capacity; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antibiotics: Intravesical instillations should be postponed during antibiotic therapy; antibiotics may reduce the efficacy of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy of intravesicular BCG have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Positive PPD reaction: Determine PPD status prior to use. BCG vaccination is not recommended for persons with a positive PPD reaction. Prior to intravesical instillation, patients with a positive PPD test should be further assessed for signs and/or symptoms of active or latent tuberculosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Latex: Packaging may contain natural latex rubber.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Biohazard agent:",
"     <b>",
"      [U.S. Boxed Warning]: Contains live, attenuated mycobacteria. Use appropriate precautions for handling and disposal. BCG is a biohazard; proper preparation technique, handling, and disposal of all equipment in contact with BCG as a biohazard material is recommended.",
"     </b>",
"     BCG infections have been reported in healthcare workers due to accidental exposure (needlestick, skin laceration); nosocomial infections have been reported in patients receiving parenteral medications prepared in areas where BCG was prepared. To avoid cross contamination, do not prepare parenteral medications in an area where BCG has been prepared.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: BCG vaccine should not be used for the active treatment of tuberculosis or for the prevention of cancer. Information not available for interchanging products used for intravesical administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F139145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antibiotics: May diminish the therapeutic effect of BCG.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Ophthalmic); Ciprofloxacin (Ophthalmic); Erythromycin (Ophthalmic); Fidaxomicin; Gatifloxacin; Gentamicin (Ophthalmic); Sulfacetamide (Ophthalmic); Tobramycin (Ophthalmic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Fingolimod may diminish the therapeutic effect of Vaccines (Live).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hexaminolevulinate: BCG may diminish the diagnostic effect of Hexaminolevulinate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hydroxychloroquine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immune Globulins: May diminish the therapeutic effect of Vaccines (Live). Management: Live organism vaccination should be withheld for up to 6 months following immune globulin administration.  Live vaccine given immediately prior to immune globulin may require repeat vaccination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     AzaTHIOprine; Beclomethasone (Oral Inhalation); Betamethasone; Budesonide (Systemic, Oral Inhalation); Corticotropin; Cortisone; Cytarabine (Liposomal); Dexamethasone (Systemic); Fludrocortisone; Fluticasone (Oral Inhalation); Hydrocortisone (Systemic); Hydroxychloroquine; Leflunomide; Mercaptopurine; Methotrexate; MethylPREDNISolone; PrednisoLONE (Systemic); PredniSONE; Triamcinolone (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of BCG.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mercaptopurine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tuberculin Tests: Vaccines (Live) may diminish the diagnostic effect of Tuberculin Tests.  Management: If a parenteral live vaccine has been recently administered, a scheduled PPD skin test should not be administered for at least 4-6 weeks following the administration of the vaccine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F139148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2830654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Both BCG intravesical and BCG vaccine are not recommended for use in pregnant women. Women of childbearing potential should be advised to avoid pregnancy while on intravesical therapy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F2830656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2830657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (TheraCys Intravesical)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     81 mg/vial (1): $204.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Tice BCG Intravesical)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (1): $174.18",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9615655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     PPD test prior to vaccination or intravesical treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Intravesical treatment: Signs and symptoms of toxicity/infection following every treatment. Signs that antituberculous therapy may be needed: Flu-like symptoms &ge;72 hours, fever &ge;101.3&deg;F, systemic symptoms which worsen with each treatment, persistently abnormal liver function tests, prostatitis, epididymitis or orchitis of &gt;2-3 day duration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Vaccination: Flu-like symptoms &ge;72 hours, fever &ge;103&deg;F, acute local reactions lasting &gt;2-3 days. Monitor for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F139159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Calgevax (BG);",
"     </li>",
"     <li>",
"      Immucyst (CN, CO, CZ, EE, GB, HK, HN, MY, PY, SG, TW);",
"     </li>",
"     <li>",
"      Oncotice (AT, BE, CH, DE, DK, FI, GR, IL, IN, IT, KP, NL, NO, PK, PL, TR);",
"     </li>",
"     <li>",
"      OncoTice (AU, NZ, VE);",
"     </li>",
"     <li>",
"      OncoTICE (MX, PE, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F139140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     BCG live is an attenuated strain of bacillus Calmette-Gu&eacute;rin (",
"     <i>",
"      Mycobacterium bovis",
"     </i>",
"     ) used as a biological response modifier. BCG live, when used intravesicularly for treatment of bladder carcinoma",
"     <i>",
"      in situ",
"     </i>",
"     , is thought to cause a local, chronic inflammatory response involving macrophage and leukocyte infiltration of the bladder. By a mechanism not fully understood, this local inflammatory response leads to destruction of superficial tumor cells of the urothelium. BCG is active immunotherapy which stimulates the host's immune mechanism to reject the tumor. Evidence of systemic immune response is also commonly seen, manifested by a positive PPD tuberculin skin test reaction, however, its relationship to clinical efficacy is not well-established.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alexandroff AB, Jackson AM, O'Donnell MA, et al, &ldquo;BCG Immunotherapy of Bladder Cancer: 20 Years On,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1999, 353(9165):1689-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/30/28135/abstract-text/10335805/pubmed\" id=\"10335805\" target=\"_blank\">",
"        10335805",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Badalament RA and Farah RN, &ldquo;Treatment of Superficial Bladder Cancer With Intravesical Chemotherapy,&rdquo;",
"      <i>",
"       Semin Surg Oncol",
"      </i>",
"      , 1997, 13(5):335-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/30/28135/abstract-text/9259089/pubmed\" id=\"9259089\" target=\"_blank\">",
"        9259089",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bassi P, &ldquo;BCG (Bacillus of Calmette Guerin) Therapy of High-Risk Superficial Bladder Cancer,&rdquo;",
"      <i>",
"       Surg Oncol",
"      </i>",
"      , 2002, 11(1-2):77-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/30/28135/abstract-text/12031870/pubmed\" id=\"12031870\" target=\"_blank\">",
"        12031870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/30/28135/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Syncope After Vaccination -- United States, January 2005-July 2007,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 57(17):457-60. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5717a2.htm\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5717a2.htm",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/30/28135/abstract-text/18451756/pubmed\" id=\"18451756\" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention,&ldquo;TB Elimination: BCG Vaccine,&rdquo; November 2008.  Available at",
"      <a href=\"file://www.cdc.gov/tb/publications/factsheets/prevention/BCG.htm\" target=\"_blank\">",
"       file://www.cdc.gov/tb/publications/factsheets/prevention/BCG.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention,&ldquo;The Role of BCG Vaccine in the Prevention and Control of Tuberculosis in the United States: A Joint Statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 1996, 45(RR-4):1-18. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/PDF/rr/rr4504.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/PDF/rr/rr4504.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/30/28135/abstract-text/8602127/pubmed\" id=\"8602127\" target=\"_blank\">",
"        8602127",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lamm DL, Steg A, Boccon-Gibod L, et al, &ldquo;Complications of Bacillus Calmette-Gu&eacute;rin Immunotherapy: Review of 2602 Patients and Comparison of Chemotherapy Complications,&rdquo;",
"      <i>",
"       Prog Clin Biol Res",
"      </i>",
"      , 1989, 310:335-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/30/28135/abstract-text/2505273/pubmed\" id=\"2505273\" target=\"_blank\">",
"        2505273",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martinez-Pineiro JA and Martinez-Pineiro L, &ldquo;BCG Update: Intravesical Therapy,&rdquo;",
"      <i>",
"       Eur Urol",
"      </i>",
"      , 1997, 31(Suppl 1):31-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/30/28135/abstract-text/9076484/pubmed\" id=\"9076484\" target=\"_blank\">",
"        9076484",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meyer JP, Persad R, and Gillatt DA, &ldquo;Use of Bacille Calmette-Guerin in Superficial Bladder Cancer,&rdquo;",
"      <i>",
"       Postgrad Med J",
"      </i>",
"      , 2002, 78(922):449-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/30/28135/abstract-text/12185215/pubmed\" id=\"12185215\" target=\"_blank\">",
"        12185215",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nathanson L, &ldquo;Use of BCG in the Treatment of Human Neoplasms: A Review,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 1974, 1(4):337-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/30/28135/abstract-text/4620439/pubmed\" id=\"4620439\" target=\"_blank\">",
"        4620439",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Bladder Cancer,&rdquo; Version 2.2012. Available at file://www.nccn.org/professionals/physician_gls/PDF/bladder.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nseyo UO and Lamm DL, &ldquo;Immunotherapy of Bladder Cancer,&rdquo;",
"      <i>",
"       Semin Surg Oncol",
"      </i>",
"      , 1997, 13(5):342-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/30/28135/abstract-text/9259090/pubmed\" id=\"9259090\" target=\"_blank\">",
"        9259090",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/30/28135/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rischmann P, Desgrandchamps F, Malavaud B, et al, &ldquo;BCG Intravesical Instillations: Recommendations for Side-Effects Management,&rdquo;",
"      <i>",
"       Eur Urol",
"      </i>",
"      , 2000, 37(Suppl 1):33-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/30/28135/abstract-text/10575271/pubmed\" id=\"10575271\" target=\"_blank\">",
"        10575271",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, &ldquo;Febrile seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008,  121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/30/28135/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9063 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-62E4DD783C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_30_28135=[""].join("\n");
var outline_f27_30_28135=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708633\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139164\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139165\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139177\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139166\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139173\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2558433\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673275\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673276\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139151\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139137\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139154\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139152\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3401584\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139175\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139156\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139141\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298815\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139145\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139148\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2830654\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2830656\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2830657\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323009\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9615655\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139159\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139140\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9063\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9063|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/39/40564?source=related_link\">",
"      Bacillus Calmette-Guerin (BCG) vaccine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_30_28136="Evaluation of stupor and coma in children";
var content_f27_30_28136=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of stupor and coma in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/30/28136/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/30/28136/contributors\">",
"     David Michelson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/30/28136/contributors\">",
"     Linda Thompson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/30/28136/contributors\">",
"     Eric Williams, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/30/28136/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/30/28136/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/30/28136/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/30/28136/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/30/28136/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coma is an alteration of consciousness in which a person appears to be asleep, cannot be aroused, and shows no awareness of the environment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28136/abstract/1\">",
"     1",
"    </a>",
"    ]. Coma is therefore the most profound degree to which the two components of consciousness, arousal and awareness, can be diminished. Less profound states of impaired consciousness (stupor, lethargy, obtundation) preserve one or more of these components to some degree.",
"   </p>",
"   <p>",
"    Coma represents an acute, life threatening emergency, requiring prompt intervention for preservation of life and brain function. Although discussed separately, the assessment and management are performed jointly in practice (",
"    <a class=\"graphic graphic_table graphicRef62416 \" href=\"UTD.htm?4/22/4461\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This topic will discuss the evaluation of children presenting in stupor or coma. Initial treatment and prognosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19544?source=see_link\">",
"     \"Treatment and prognosis of coma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     States of impaired consciousness",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a spectrum of impaired consciousness between full arousal and complete unresponsiveness.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coma, a state of \"unarousable unresponsiveness,\" is the most profound degree to which arousal and consciousness are impaired [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28136/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lethargy, obtundation, and stupor refer to states in which arousal is somewhat less impaired. These patients have some difficulty maintaining attention during an examination, tend to fall asleep when not stimulated, and respond poorly (if at all) to questions and commands. These terms are imprecise. In clinical situations, it is more useful to describe the patient's responses to specific stimuli.",
"     </li>",
"     <li>",
"      Delirium is a disturbance of consciousness with reduced ability to focus, sustain, or shift attention. Patients show both hyperactivity and diminished sleep. Confusion, excitement, hallucinations, and irritability are common. Delirium is caused by a subset of conditions that can lead to coma, including medical conditions, substance intoxications, and medication side effects. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22506?source=see_link\">",
"       \"Acute toxic-metabolic encephalopathy in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Coma sequelae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coma is a transient state. Patients recover, die, or evolve into a more permanent state of impaired consciousness:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persistent vegetative state (PVS) describes patients who are completely unconscious but have spontaneous eye opening during cyclical periods of arousal [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28136/abstract/2\">",
"       2",
"      </a>",
"      ]. Such patients often have reflexive vocalizations (sounds but not words), facial expressions, and movements that can be misinterpreted by hopeful observers as reflecting awareness of their internal or external environment [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28136/abstract/3\">",
"       3",
"      </a>",
"      ]. Required features of PVS are [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28136/abstract/3-8\">",
"       3-8",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      No evidence of awareness of self or environment and no ability to interact with others.",
"     </li>",
"     <li>",
"      No evidence of sustained, reproducible, purposeful, or voluntary behavioral responses to visual, auditory, tactile, or noxious stimuli.",
"     </li>",
"     <li>",
"      No evidence of language comprehension or expression.",
"     </li>",
"     <li>",
"      Intermittent wakefulness manifested by the presence of sleep-wake cycles.",
"     </li>",
"     <li>",
"      Sufficiently preserved hypothalamic and brainstem autonomic function to permit survival with medical and nursing care.",
"     </li>",
"     <li>",
"      Bowel and bladder incontinence.",
"     </li>",
"     <li>",
"      Variably preserved cranial nerve reflexes and spinal reflexes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The minimally conscious state describes patients with severe alteration in consciousness who do not meet criteria for PVS [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28136/abstract/9\">",
"       9",
"      </a>",
"      ]. They can at least occasionally demonstrate purposeful movements or responses. This can include following simple commands, making gestural or verbal responses to questions, making intelligible verbalizations, smiling or crying in response to evocative sounds or images, reaching accurately toward the location of an object, or fixating on and pursuing visual stimuli [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28136/abstract/10\">",
"       10",
"      </a>",
"      ]. Functional neuroimaging studies suggest that these patients have a different, less severe, neuroanatomic substrate than do patients in PVS [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28136/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Brain death criteria include coma, apnea, and absent brainstem reflexes. A diagnosis of brain death specifically implies no chance of recovery and is synonymous with death in most countries. Age-specific diagnostic criteria exist. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30761?source=see_link&amp;anchor=H21#H21\">",
"       \"Diagnosis of brain death\", section on 'Brain death in children'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Conditions mistaken for coma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some conditions can be mistaken for coma because the child is unable to respond voluntarily, despite maintaining some degree of arousal and awareness. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete paralysis. Patients with acute lesions of the brainstem, particularly the pons, may be unable to move or speak while retaining awareness. Voluntary vertical eye movements and blinking may be retained. This condition is often called the \"locked-in\" state. Other causes of severe motor paralysis (eg, Guillain-Barre syndrome, botulism) may also cause a similar condition.",
"     </li>",
"     <li>",
"      Akinetic-mutism or abulia may be produced by lesions in the portions of the frontal lobes responsible for initiating movement. The patient retains awareness and often tracks movements with the eyes but rarely initiates other movements or obeys commands. Tone, reflexes, and postural reflexes usually remain intact.",
"     </li>",
"     <li>",
"      Psychiatric unresponsiveness and catatonia are unusual in very young patients but may occur in adolescents. These patients often resist passive eye opening, move to avoid noxious stimuli, turn the eyes towards the floor regardless of which side they are lying on, or have nonepileptic seizures. Catatonia is distinguished from coma by the preserved ability to maintain trunk and limb postures, even the ability to sit or stand.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A careful neurologic examination can distinguish these entities from coma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ETIOLOGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arousal depends on intact communication between the ascending reticular activating system (ARAS) and its targets in the hypothalamus, thalamus, and cerebral cortex. The ARAS is a loosely organized network of neurons within the brainstem whose major function is to modulate arousal in response to signals from the environment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28136/abstract/12\">",
"     12",
"    </a>",
"    ]. Awareness is based on an even more widely distributed network of connections between cortical and subcortical structures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28136/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consciousness can be diminished or abolished by dysfunction within the brainstem, impairment of both cerebral hemispheres, or by insults that globally depress neuronal activity. The latter include metabolic disturbances and disorders that deplete substrates for cerebral metabolism, alter neuronal cell homeostasis, or interfere with neuronal excitability. Unilateral cerebral lesions may cause coma if they compress or injure contralateral or brainstem structures.",
"   </p>",
"   <p>",
"    A list of potential etiologies of coma is presented in the table (",
"    <a class=\"graphic graphic_table graphicRef65571 \" href=\"UTD.htm?39/19/40254\">",
"     table 2",
"    </a>",
"    ). Traumatic and nontraumatic causes of coma have roughly equal annual incidences of about 30 per 100,000 children each [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28136/abstract/14\">",
"     14",
"    </a>",
"    ]. Nontraumatic causes are more frequent in infancy and early childhood, when congenital heart malformations and inborn errors of metabolism are most likely to become symptomatic first.",
"   </p>",
"   <p>",
"    In a prospective, population-based study of nontraumatic coma in 278 children, infection was the most common etiology (38 percent of cases), and",
"    <em>",
"     Neisseria meningitidis",
"    </em>",
"    was the most common identified pathogen, in 47 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28136/abstract/14\">",
"     14",
"    </a>",
"    ]. An exogenous toxin (accidental and deliberate intoxication) was the second most common cause overall (10 percent of cases) but was the most common cause in adolescents (35 percent of cases). Seizures, congenital heart or brain malformations, accidents (eg, drowning, smoke inhalation), hypoxic-ischemic injury, and metabolic disorders (eg, diabetes, inborn errors of metabolism) were other common etiologies. In another study from India describing 100 children in coma, infection was again the most common etiology, seen in 60 percent of cases; there,",
"    <em>",
"     Mycobacterium tuberculosis",
"    </em>",
"    was the most common pathogen [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28136/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coma is a medical emergency whose evaluation requires a rapid, comprehensive, and systematic approach. Early identification of the underlying cause of coma can be crucial for patient management and prognosis. Although discussed separately, the assessment and management are performed jointly in practice (",
"    <a class=\"graphic graphic_table graphicRef62416 \" href=\"UTD.htm?4/22/4461\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology may be apparent from the history, such as when coma results from the expected progression or complication of a known illness or injury [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28136/abstract/9\">",
"     9",
"    </a>",
"    ]. Examples include a child with diabetes presenting with hypoglycemic coma or with cerebral edema from hyperglycemic ketoacidosis; or a child with cyanotic congenital heart disease presenting with coma due to embolic brain abscesses or infarctions.",
"   </p>",
"   <p>",
"    The history of symptoms leading up to coma may also provide clues. Coma of abrupt and unexplained onset suggests intracranial hemorrhage, seizure, cardiac arrhythmia, trauma, or intoxication. Inborn errors of metabolism may present with slowly evolving coma or recurrent episodic coma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28136/abstract/16\">",
"     16",
"    </a>",
"    ]. A gradual deterioration of mental status may also suggest an infectious process, metabolic abnormality, or slowly expanding intracranial mass lesion. A history of preceding headache, double vision, or nausea suggests increased intracranial pressure. A history from the caregiver that is vague or inconsistent with the examination may engender suspicion for non-accidental trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28136/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=see_link\">",
"     \"Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Toxic ingestions in young children are often unwitnessed, and parents should be questioned regarding the possibility of available substances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     General examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessing vital signs and the ABCs: airway patency, breathing (ventilation and oxygenation), and circulation, are crucial for initial stabilization, but may also provide clues about the underlying etiology:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Temperature &mdash; Hyperthermia suggests infection, but is also seen with inflammatory disorders, environmental or exertional heat stroke, neuroleptic malignant syndrome, status epilepticus, hyperthyroidism, and anticholinergic poisoning. When infection is suspected, possible complications such as intracranial seeding, septic shock, seizures, Reye syndrome, and exacerbation of an underlying metabolic disorder should also be considered.",
"      <br/>",
"      <br/>",
"      Hypothermia can occur with infection in infants but is more often due to drug intoxication, environmental exposure, or hypothyroidism. Hypothermia itself blunts cognitive function and arousal, presumably by decreasing cerebral blood flow.",
"     </li>",
"     <li>",
"      Heart rate &mdash; Tachycardia can occur with fever, pain, hypovolemia, cardiomyopathy, tachyarrhythmia, and also in status epilepticus. Bradycardia occurs with hypoxemia, hypoxic ischemic myocardial injury, and with increased intracranial pressure (ICP) as part of Cushing's triad (bradycardia, hypertension, irregular respirations).",
"     </li>",
"     <li>",
"      Respirations &mdash; Tachypnea can be seen with pain, hypoxia, metabolic acidosis, and pontine injury. Slow, irregular, or periodic respirations occur with metabolic alkalosis, diabetic ketoacidosis, sedative intoxication, and injury to extrapontine portions of the brainstem. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Coma syndromes'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Blood pressure &mdash; Hypotension suggests hypovolemic, septic, or cardiogenic shock, intoxication, or adrenal insufficiency. Impaired consciousness may be an early indicator of poor end-organ perfusion in a patient with shock. When cerebral blood flow (CBF) falls to less than half normal, oxygen delivery is insufficient for normal oxidative metabolism, patients lose consciousness, and EEG activity is suppressed. Further decline in CBF may cause irreversible neuronal injury unless prompt intervention restores circulation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28136/abstract/18,19\">",
"       18,19",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Hypertension may be due to pain, intoxication, renal failure, or increased ICP.",
"     </li>",
"     <li>",
"      Skin &mdash; A complete skin examination can be particularly helpful (",
"      <a class=\"graphic graphic_table graphicRef79446 \" href=\"UTD.htm?42/16/43276\">",
"       table 3",
"      </a>",
"      ). Abnormal skin color accompanies hypoxia (blue), jaundice (yellow), anemia (pale), and carbon-monoxide poisoning (cherry-red). Bruising and evidence of other orthopedic injury suggests trauma. Periorbital bruising (raccoon eyes), mastoid bruising (battle sign), or cerebrospinal fluid (CSF) from the nose (rhinorrhea) or ear (otorrhea) suggests head injury with skull fracture. Particular rashes may suggest various infections.",
"     </li>",
"     <li>",
"      Fundoscopy &mdash; Papilledema suggests increased intracranial pressure of more than several hours duration [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28136/abstract/20\">",
"       20",
"      </a>",
"      ]. Retinal hemorrhages are most commonly associated with shaken baby syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=see_link\">",
"       \"Child abuse: Eye findings in children with abusive head trauma (AHT)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=see_link\">",
"       \"Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Meningismus &mdash; Meningeal irritation or inflammation suggesting meningitis or subarachnoid hemorrhage is demonstrated by passive resistance to neck flexion (nuchal rigidity), involuntary knee flexion with forced hip flexion (Kernig's sign), or involuntary hip and knee flexion with forced neck flexion (Brudzinski's sign). These signs are often absent in infants and young children [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28136/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Neurologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neurologic examination in this situation is necessarily brief and is directed at determining whether the pathology is structural or due to a systemic metabolic derangement (including drug toxicity or infection). The examiner assesses:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Level of consciousness",
"     </li>",
"     <li>",
"      Motor responses",
"     </li>",
"     <li>",
"      Brainstem reflexes: pupillary responses to light, extraocular movements, and corneal reflexes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Important findings are abnormal reflexes that indicate dysfunction in specific regions of the brainstem",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    impending transtentorial herniation, or a consistent asymmetry between right- and left-sided responses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14618?source=see_link&amp;anchor=H10928992#H10928992\">",
"     \"Detailed neurologic assessment of infants and children\", section on 'Neurologic examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Pupils",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pupillary reflex depends on intact transmission within the afferent optic nerve (cranial nerve II), the Edinger Westphal nucleus in the midbrain, and the efferent oculomotor nerve (cranial nerve III). Parasympathetic impulses constrict the pupils, while sympathetic discharge (originating in the hypothalamus) leads to pupillary dilation.",
"   </p>",
"   <p>",
"    Anisocoria suggests a brainstem insult or a supratentorial lesion that is causing compression of the oculomotor nerve or nucleus within the brainstem. Small, reactive pupils can be seen with metabolic disorders and certain intoxications (",
"    <a class=\"graphic graphic_table graphicRef71268 \" href=\"UTD.htm?43/6/44140\">",
"     table 4",
"    </a>",
"    ). Bilaterally fixed pupils that are either midposition or dilated can be seen with severe afferent defects but are most often seen with brainstem insults that disrupt both the sympathetic and parasympathetic control of the eyes. Sympathomimetic and anticholinergic drugs also cause dilated pupils (",
"    <a class=\"graphic graphic_table graphicRef71268 \" href=\"UTD.htm?43/6/44140\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Eye movements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extraocular movements are controlled by the oculomotor, trochlear, and abducens nerves (cranial nerves III, IV, and VI). Conjugate lateral eye movements are coordinated by the parapontine reticular formations and the medial longitudinal fasciculi. Voluntary lateral eye movements are directed by the contralateral frontal eye field. Reflex movements arise from a combination of visual, proprioceptive, and vestibular inputs to the brainstem and cerebellum.",
"   </p>",
"   <p>",
"    Persistent conjugate eye deviation to one side may suggest injury to the ipsilateral cerebral hemisphere or ongoing seizure activity arising from the contralateral hemisphere. Accompanying nystagmus also suggests seizure.",
"   </p>",
"   <p>",
"    The presence of bilateral conjugate roving eye movements which appear full indicate an intact brainstem and further reflex testing is not required. Otherwise eye movements can be tested in comatose patients using reflex maneuvers:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the oculocephalic (doll's eye) reflex, the head is rotated to one side. With an intact brainstem, the eyes do not turn with the head but move in the opposite direction, thus appearing to maintain visual fixation (",
"      <a class=\"graphic graphic_figure graphicRef61416 \" href=\"UTD.htm?38/40/39555\">",
"       figure 1",
"      </a>",
"      ). When comatose patients have possible cervical spine injury, this reflex should not be tested. An abnormal response suggests a lesion within the brainstem or cranial nerves; profound metabolic coma or drug intoxication can also impair this reflex.",
"     </li>",
"     <li>",
"      The oculovestibular (caloric) reflex test assesses the same pathways. Otoscopy should first confirm that the external ear canals are patent and the tympanic membranes are intact. With the head at 30 degrees elevation from horizontal, irrigation of the external ear canal with ice-cold water (10 to 30 mL) induces slow deviation of the eyes toward the irrigated side (",
"      <a class=\"graphic graphic_figure graphicRef61416 \" href=\"UTD.htm?38/40/39555\">",
"       figure 1",
"      </a>",
"      ). Five minutes should intervene before the other side is tested. Failure of the eyes to move conjugately as expected suggests a lesion of one or more cranial nerves or their nuclei within the brainstem. Conscious patients also have saccadic eye movements back toward midline that attempt to maintain visual fixation. When this occurs in an unresponsive patient, a psychogenic origin is suspected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Other brainstem reflexes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The corneal reflex tests the sensory function of the trigeminal nerve and the motor function of the facial nerve. The patient's cornea is lightly touched with a fine wisp of cotton or a drop of sterile water; an intact reflex produces a bilateral (direct and consensual) eye blink. Bilaterally absent corneal reflexes can be seen with extensive structural lesions within the pons, but also occur with metabolic disorders, intoxication, sedation, and paralysis.",
"   </p>",
"   <p>",
"    The gag reflex requires intact function of the glossopharyngeal and vagal nerves (cranial nerves IX and X), and produces palate elevation with stimulation of each side of the posterior wall of the oropharynx. When a patient is intubated, endotracheal tube manipulation or suctioning to elicit a cough is often used as an alternative. However, cervical spinal cord reflexes can also mediate this response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Motor responses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The motor examination in the comatose child should assess muscle tone, observe spontaneous and stimulus-elicited movements, and test deep tendon reflexes. Painful stimuli (eg, pressure applied to nail bed or supraorbital ridge) are often used to elicit motor responses in an unconscious child. Asymmetries may suggest involvement of the corticospinal tracts in the cerebral hemisphere or brainstem. The presence of spontaneous or purposeful limb movements (eg, withdrawing from or pushing away a painful stimulus) suggests a lighter depth of coma.",
"   </p>",
"   <p>",
"    Abnormal flexion or extension of the arms and legs may occur spontaneously or in response to stimulation. Decerebrate posturing includes extension and internal rotation of the arms and legs; decorticate posturing produces adduction and flexion at the elbows, wrists and fingers, with leg extension and rotation (",
"    <a class=\"graphic graphic_figure graphicRef61697 \" href=\"UTD.htm?9/31/9717\">",
"     figure 2",
"    </a>",
"    ). Classically, decerebrate posturing implies brainstem involvement from a compressive or destructive process, while decorticate posturing implies a more rostral and potentially less dire insult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Rating Scales",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Glasgow Coma Scale (GCS) and its modification for young children less than five years, the Pediatric Coma Scale (PCS), both grade coma severity according to three categories of responsiveness: eye opening, motor, and verbal responses (",
"    <a class=\"graphic graphic_table graphicRef59662 \" href=\"UTD.htm?2/58/2989\">",
"     table 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28136/abstract/13,22-24\">",
"     13,22-24",
"    </a>",
"    ]. These have descriptive value for depth of coma, but omit aspects of the neurological examination important for diagnosis and management. An expanded scale, the FOUR Score, has been developed and validated but is not widely used [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28136/abstract/25\">",
"     25",
"    </a>",
"    ]. While not useful for diagnosis, the GCS has been linked to prognosis for a number of conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19544?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment and prognosis of coma in children\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Coma syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain coma syndromes are important to recognize as they may guide diagnostic evaluation and initial management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Transtentorial herniation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond early infancy, when open fontanelles and sutures allow limited expansion, the skull is a fixed structure that cannot accommodate volume expansion. Large and rapid expansions induce dramatic increases in intracranial pressure and may lead to transtentorial herniation.",
"   </p>",
"   <p>",
"    Two variants are recognized: a central herniation syndrome and an uncal herniation syndrome. In the latter, more laterally directed compressive forces lead to asymmetric herniation of the uncus of the temporal lobe, producing the early appearance of third cranial nerve palsy. Hemiplegia due to compression of the corticospinal tract in the midbrain often follows immediately. The syndrome then follows the sequence of central herniation (",
"    <a class=\"graphic graphic_figure graphicRef76974 \" href=\"UTD.htm?5/13/5335\">",
"     figure 3",
"    </a>",
"    ). Generally, survival does not occur once herniation has reached a lower pontine level [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28136/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other signs of increased intracranial pressure (ICP), papilledema, and Cushing's triad (hypertension, bradycardia, and irregular respirations) may be observed in this setting.",
"   </p>",
"   <p>",
"    Some metabolic derangements, intoxications, and seizure states may mimic the early signs of central herniation. Treating all children with these signs as if further herniation is imminent avoids missing an opportunity for preventing irreversible brainstem injury and death [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28136/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Metabolic encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolic coma usually occurs as a progression from delirium to stupor to coma, but more fulminant cases may present in coma. A fluctuating examination is common; deficits can include abnormal brainstem reflexes, hypotonia, and even posturing in severe cases. Asymmetries in the examination and pupillary involvement are uncommon in metabolic coma. Multifocal myoclonus is very suggestive of a metabolic etiology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22506?source=see_link\">",
"     \"Acute toxic-metabolic encephalopathy in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Toxidromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some toxic ingestions are recognized by specific clinical syndromes or toxidromes (",
"    <a class=\"graphic graphic_table graphicRef71268 \" href=\"UTD.htm?43/6/44140\">",
"     table 4",
"    </a>",
"    ). However, children are more likely than adults to present with atypical clinical features [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28136/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although discussed separately, the assessment and management are performed jointly in practice (",
"    <a class=\"graphic graphic_table graphicRef62416 \" href=\"UTD.htm?4/22/4461\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Studies can be guided by history and physical exam findings, but most patients presenting with coma of unknown etiology require laboratory testing and a neuroimaging study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Laboratory Testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients presenting with altered consciousness should undergo a rapid bedside test for blood glucose and basic laboratory testing including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum electrolytes, calcium, magnesium, glucose",
"     </li>",
"     <li>",
"      Arterial blood gas",
"     </li>",
"     <li>",
"      Liver function tests, ammonia",
"     </li>",
"     <li>",
"      Complete blood count",
"     </li>",
"     <li>",
"      Blood urea nitrogen, creatinine",
"     </li>",
"     <li>",
"      Urine drug screen",
"     </li>",
"     <li>",
"      Blood culture",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In suspected metabolic abnormalities, or if the diagnosis remains obscure after initial testing, urine porphyrins, ketone bodies, plasma free fatty acids,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"     carnitine",
"    </a>",
"    , creatine kinase, lactate, pyruvate, serum amino acids, and urine organic acids should be obtained. For some metabolic diseases, abnormal test results may only occur when the child is acutely symptomatic; in likely cases, testing should not be delayed.",
"   </p>",
"   <p>",
"    If infection is a possibility, blood and urine should be tested for bacterial and viral pathogens. Testing for fungi, rickettsia, mycobacteria, and parasites should be considered in individuals with compromised immunity or suspected exposures.",
"   </p>",
"   <p>",
"    Urine drug screens test for common drugs of abuse. Broader drug screens, such as thin-layer chromatography and ultraviolet spectroscopy, can detect less common causes of intoxication, and specific drug levels can often be obtained if specific ingestions are suspected.",
"   </p>",
"   <p>",
"    Other tests of potential utility in specific situations include thyroid function tests, cortisol levels, carboxyhemoglobin levels for possible carbon monoxide poisoning, and coagulation studies (prothrombin and partial thromboplastin times, blood smear, screen for disseminated intravascular coagulation, D-dimer, fibrinogen determination, and antiphospholipid antibody titers) if a coagulopathy is suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) is the best initial neuroimaging test for evaluating a child in unexplained coma. CT quickly detects pathology in need of immediate surgical intervention, including hydrocephalus, herniation, and mass lesions due to infection, neoplasia, hemorrhage, and edema. CT should be performed immediately when the examination suggests increased intracranial pressure (papilledema, bulging fontanelle in infants, or bradycardia with hypertension) or a transtentorial herniation syndrome (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Transtentorial herniation'",
"    </a>",
"    above). When lumbar puncture is indicated, a CT is required in the comatose patient to rule out a mass lesion that might precipitate transtentorial herniation as a result of the procedure.",
"   </p>",
"   <p>",
"    Magnetic resonance imaging (MRI) provides greater structural detail and is more sensitive for early evidence of encephalitis, infarction, diffuse axonal injury from head injury, petechial hemorrhages, cerebral venous thrombosis, and demyelination [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28136/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. When initial testing (CT, laboratory studies) does not provide a definitive diagnosis, MRI can be helpful. Additional neuroimaging studies may be suggested by the history or initial CT or MRI, such as MR, CT, or conventional angiography for cases of suspected vascular malformation, vasculitis, or venous thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28136/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=see_link\">",
"     \"Etiology, clinical features, and diagnosis of cerebral venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MRI may also offer information regarding prognosis in patients with anoxic or traumatic coma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19544?source=see_link\">",
"     \"Treatment and prognosis of coma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Repeat scanning, usually with CT, is often done emergently in patients with clinical deterioration to demonstrate or exclude worsening edema, hemorrhage, herniation, or hydrocephalus. However, patients without a surgically remediable lesion on initial 24 or 48 hour CT scans do not appear to benefit from continued routine imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28136/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Lumbar puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urgent evaluation of cerebrospinal fluid (CSF) is required when there is suspected infection of the central nervous system. In a patient with altered level of consciousness, neuroimaging to exclude an intracranial mass lesion is required prior to lumbar puncture (LP) in order to avoid precipitating transtentorial herniation. Coagulation test results should also be obtained beforehand. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/1/25625?source=see_link\">",
"     \"Lumbar puncture: Indications, contraindications, technique, and complications in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Empiric antimicrobial treatment is recommended when the diagnosis of bacterial meningitis or herpes encephalitis is strongly suspected, as early treatment improves prognosis of these conditions (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19544?source=see_link\">",
"     \"Treatment and prognosis of coma in children\"",
"    </a>",
"    ). Treatment may impair the diagnostic sensitivity of CSF cultures but should not affect other tests (WBC, gram stain, PCR). Blood cultures should be obtained prior to antibiotic intervention, as they have at least a 50 percent yield in bacterial meningitis (",
"    <a class=\"graphic graphic_algorithm graphicRef74865 \" href=\"UTD.htm?34/44/35521\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28136/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38458?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment and prognosis of acute bacterial meningitis in children older than one month of age\", section on 'Empiric therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Electroencephalogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;EEG should be performed in children with coma of unknown etiology. It is often the only means of recognizing nonconvulsive status epilepticus (NCSE), especially in patients who are paralyzed.",
"   </p>",
"   <p>",
"    Periodic epileptiform discharges may occur in NCSE but also in underlying brain injury without seizures. Periodic lateralized epileptiform discharges (",
"    <a class=\"graphic graphic_waveform graphicRef62133 \" href=\"UTD.htm?14/26/14761\">",
"     waveform 1",
"    </a>",
"    ) suggest herpes encephalitis or infarction. Multifocal or generalized periodic discharges (",
"    <a class=\"graphic graphic_waveform graphicRef66411 \" href=\"UTD.htm?16/9/16537\">",
"     waveform 2",
"    </a>",
"    ) can also be seen with metabolic and infectious etiologies and are characteristic of subacute sclerosing panencephalitis.",
"   </p>",
"   <p>",
"    Nonepileptiform features of the EEG, such as slowing or asymmetry, are largely nonspecific findings, but can sometimes provide diagnostic or prognostic information. Continuous EEG can be used to assess and titrate the depth of sedation in patients placed under anesthesia for control of status epilepticus or increased ICP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28136/abstract/35-39\">",
"     35-39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19544?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment and prognosis of coma in children\", section on 'Electroencephalogram'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link&amp;anchor=H27#H27\">",
"     \"Elevated intracranial pressure in children\", section on 'Barbiturate coma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/1/37905?source=see_link\">",
"       \"Patient information: Coma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stupor and coma are alterations in arousal; these are neurologic emergencies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Causes of coma are diverse and include structural brain disease and systemic disease. Trauma, infections, metabolic derangements, and intoxications are the most common etiologies of coma in children. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Etiologies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A complete history and physical examination can provide valuable clues as to the underlying etiology. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'History'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'General examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The neurologic examination in coma patients includes assessment of arousal, motor examination, and cranial nerve reflexes. Important findings are abnormal reflexes that indicate dysfunction in specific regions of the brainstem, or a consistent asymmetry between right- and left-sided responses, which indicates structural brain pathology as a cause. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Neurologic examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation and early therapeutic interventions should proceed promptly, even simultaneously. A protocol for urgent evaluation and management is recommended (",
"      <a class=\"graphic graphic_table graphicRef62416 \" href=\"UTD.htm?4/22/4461\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Plum, F, Posner, JB. The Diagnosis of Stupor and Coma III. FA Davis, Philadelphia, 1980. p.2.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/2\">",
"      Zeman A. Persistent vegetative state. Lancet 1997; 350:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/3\">",
"      Medical aspects of the persistent vegetative state (1). The Multi-Society Task Force on PVS. N Engl J Med 1994; 330:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/4\">",
"      Laureys S, Owen AM, Schiff ND. Brain function in coma, vegetative state, and related disorders. Lancet Neurol 2004; 3:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/5\">",
"      Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet 1975; 1:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/6\">",
"      Levy DE, Bates D, Caronna JJ, et al. Prognosis in nontraumatic coma. Ann Intern Med 1981; 94:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/7\">",
"      Jennett B, Plum F. Persistent vegetative state after brain damage. A syndrome in search of a name. Lancet 1972; 1:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/8\">",
"      Medical aspects of the persistent vegetative state (2). The Multi-Society Task Force on PVS. N Engl J Med 1994; 330:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/9\">",
"      Bates D. The management of medical coma. J Neurol Neurosurg Psychiatry 1993; 56:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/10\">",
"      Andrews K, Murphy L, Munday R, Littlewood C. Misdiagnosis of the vegetative state: retrospective study in a rehabilitation unit. BMJ 1996; 313:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/11\">",
"      Ashwal S. Medical aspects of the minimally conscious state in children. Brain Dev 2003; 25:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/12\">",
"      Moruzzi G, Magoun HW. Brain stem reticular formation and activation of the EEG. Electroencephalogr Clin Neurophysiol 1949; 1:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/13\">",
"      Zeman A. Consciousness. Brain 2001; 124:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/14\">",
"      Wong CP, Forsyth RJ, Kelly TP, Eyre JA. Incidence, aetiology, and outcome of non-traumatic coma: a population based study. Arch Dis Child 2001; 84:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/15\">",
"      Bansal A, Singhi SC, Singhi PD, et al. Non traumatic coma. Indian J Pediatr 2005; 72:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/16\">",
"      Taylor DA. Coma in the pediatric patient: evaluation and management. Indian J Pediatr 1994; 61:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/17\">",
"      Carty H, Pierce A. Non-accidental injury: a retrospective analysis of a large cohort. Eur Radiol 2002; 12:2919.",
"     </a>",
"    </li>",
"    <li>",
"     Stubgen, JP and Plum, F. Coma. In: Textbook of Critical Care Medicine, 5th ed, Fink, MP, Abraham, E, Vincent, JL, Kochanek, PM (Eds), Elsevier Saunders, Philadelphia 2005. p.295.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/19\">",
"      Markus HS. Cerebral perfusion and stroke. J Neurol Neurosurg Psychiatry 2004; 75:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/20\">",
"      Kirkham FJ. Non-traumatic coma in children. Arch Dis Child 2001; 85:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/21\">",
"      Pong A, Bradley JS. Bacterial meningitis and the newborn infant. Infect Dis Clin North Am 1999; 13:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/22\">",
"      Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet 1974; 2:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/23\">",
"      Simpson D, Reilly P. Pediatric coma scale. Lancet 1982; 2:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/24\">",
"      Hahn YS, Chyung C, Barthel MJ, et al. Head injuries in children under 36 months of age. Demography and outcome. Childs Nerv Syst 1988; 4:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/25\">",
"      Wijdicks EF, Bamlet WR, Maramattom BV, et al. Validation of a new coma scale: The FOUR score. Ann Neurol 2005; 58:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/26\">",
"      Abbruzzi G, Stork CM. Pediatric toxicologic concerns. Emerg Med Clin North Am 2002; 20:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/27\">",
"      Tong KA, Ashwal S, Holshouser BA, et al. Hemorrhagic shearing lesions in children and adolescents with posttraumatic diffuse axonal injury: improved detection and initial results. Radiology 2003; 227:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/28\">",
"      Sundgren PC, Reinstrup P, Romner B, et al. Value of conventional, and diffusion- and perfusion weighted MRI in the management of patients with unclear cerebral pathology, admitted to the intensive care unit. Neuroradiology 2002; 44:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/29\">",
"      Ghahreman A, Bhasin V, Chaseling R, et al. Nonaccidental head injuries in children: a Sydney experience. J Neurosurg 2005; 103:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/30\">",
"      Tong KA, Ashwal S, Holshouser BA, et al. Diffuse axonal injury in children: clinical correlation with hemorrhagic lesions. Ann Neurol 2004; 56:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/31\">",
"      S&eacute;bire G, Tabarki B, Saunders DE, et al. Cerebral venous sinus thrombosis in children: risk factors, presentation, diagnosis and outcome. Brain 2005; 128:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/32\">",
"      Figg RE, Burry TS, Vander Kolk WE. Clinical efficacy of serial computed tomographic scanning in severe closed head injury patients. J Trauma 2003; 55:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/33\">",
"      Kaups KL, Davis JW, Parks SN. Routinely repeated computed tomography after blunt head trauma: does it benefit patients? J Trauma 2004; 56:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/34\">",
"      Talan DA, Hoffman JR, Yoshikawa TT, Overturf GD. Role of empiric parenteral antibiotics prior to lumbar puncture in suspected bacterial meningitis: state of the art. Rev Infect Dis 1988; 10:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/35\">",
"      Markand ON. Pearls, perils, and pitfalls in the use of the electroencephalogram. Semin Neurol 2003; 23:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/36\">",
"      Young GB. The EEG in coma. J Clin Neurophysiol 2000; 17:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/37\">",
"      Mewasingh LD, Christophe C, Fonteyne C, et al. Predictive value of electrophysiology in children with hypoxic coma. Pediatr Neurol 2003; 28:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/38\">",
"      Brenner RP. Is it status? Epilepsia 2002; 43 Suppl 3:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28136/abstract/39\">",
"      Yemisci M, Gurer G, Saygi S, Ciger A. Generalised periodic epileptiform discharges: clinical features, neuroradiological evaluation and prognosis in 37 adult patients. Seizure 2003; 12:465.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6225 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-115.25.216.6-E05BAE8337-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_30_28136=[""].join("\n");
var outline_f27_30_28136=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      States of impaired consciousness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Coma sequelae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Conditions mistaken for coma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ETIOLOGIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      General examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Neurologic examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Pupils",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Eye movements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Other brainstem reflexes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Motor responses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Rating Scales",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Coma syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Transtentorial herniation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Metabolic encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Toxidromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIAGNOSTIC STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Laboratory Testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Lumbar puncture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Electroencephalogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6225\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6225|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?34/44/35521\" title=\"algorithm 1\">",
"      Management of suspected meningitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6225|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/40/39555\" title=\"figure 1\">",
"      Oculocephalic and caloric responses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/31/9717\" title=\"figure 2\">",
"      Decerebrate and decorticate postures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/13/5335\" title=\"figure 3\">",
"      Transtentorial herniation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6225|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/22/4461\" title=\"table 1\">",
"      Initial coma eval and Rx childr",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/19/40254\" title=\"table 2\">",
"      Causes of coma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/16/43276\" title=\"table 3\">",
"      Skin lesions and rashes in coma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/6/44140\" title=\"table 4\">",
"      Poisoning syndromes - toxidromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/58/2989\" title=\"table 5\">",
"      Glasgow and pediatric coma scales",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6225|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?14/26/14761\" title=\"waveform 1\">",
"      EEG periodic lateralized epileptiform discharges PLEDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?16/9/16537\" title=\"waveform 2\">",
"      Generalized periodic epileptiform discharges",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22506?source=related_link\">",
"      Acute toxic-metabolic encephalopathy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=related_link\">",
"      Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=related_link\">",
"      Child abuse: Eye findings in children with abusive head trauma (AHT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14618?source=related_link\">",
"      Detailed neurologic assessment of infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30761?source=related_link\">",
"      Diagnosis of brain death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=related_link\">",
"      Elevated intracranial pressure in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=related_link\">",
"      Etiology, clinical features, and diagnosis of cerebral venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/1/25625?source=related_link\">",
"      Lumbar puncture: Indications, contraindications, technique, and complications in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/1/37905?source=related_link\">",
"      Patient information: Coma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38458?source=related_link\">",
"      Treatment and prognosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19544?source=related_link\">",
"      Treatment and prognosis of coma in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_30_28137="Birth center consent 2";
var content_f27_30_28137=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 623px\">",
"   <div class=\"ttl\">",
"    Birth center consent form (continued)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 603px; height: 720px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the American Association of Birth Centers. Copyright &copy;2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_30_28137=[""].join("\n");
var outline_f27_30_28137=null;
var title_f27_30_28138="Treatment of the Raynaud phenomenon resistant to initial therapy";
var content_f27_30_28138=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Treatment of the Raynaud phenomenon resistant to initial therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/30/28138/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/30/28138/contributors\">",
"     Fredrick M Wigley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/30/28138/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/30/28138/contributors\">",
"     John S Axford, DSc, MD, FRCP, FRCPCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/30/28138/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/30/28138/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/30/28138/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H3060071\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Raynaud phenomenon (RP) is an exaggerated vascular response to cold temperature or to emotional stress, which is manifested clinically by sharply demarcated color changes of the skin of the digits. Treatment includes patient education and general measures taken by the patient to prevent and treat attacks and may include pharmacologic interventions and surgical sympathetic blockade to prevent and treat digital ischemia.",
"   </p>",
"   <p>",
"    The treatment of RP in patients resistant to initial therapy is reviewed here. The initial therapy of RP, including general measures, the use of calcium channel blockers, and behavioral interventions, as well as the pathogenesis, clinical manifestations, and diagnosis of RP, is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28200?source=see_link\">",
"     \"Initial treatment of the Raynaud phenomenon\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23719?source=see_link\">",
"     \"Pathogenesis of the Raynaud phenomenon\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the Raynaud phenomenon\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3060078\">",
"    <span class=\"h1\">",
"     PRIMARY AND SECONDARY RP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Raynaud phenomenon (RP) is considered primary if the symptoms occur alone without any associated disorder; secondary RP refers to the presence of the disorder in association with a related illness, such as systemic lupus erythematosus or systemic sclerosis (scleroderma). Primary RP is sometimes also referred to as idiopathic RP or Raynaud disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the Raynaud phenomenon\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with primary RP are generally not significantly disabled by the attacks, although the quality of life may be affected by the need for cold avoidance and by the lack of normal finger sensation. An initially conservative, nonpharmacologic approach is, therefore, most important for these patients, although pharmacologic therapy may ultimately be necessary. By comparison, patients with secondary RP are more likely to have severe attacks, and disease management is more likely to be based upon pharmacologic agents, while continuing nonpharmacologic measures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3060085\">",
"    <span class=\"h1\">",
"     GOALS AND OVERVIEW OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of therapy are to improve quality of life and to prevent ischemic tissue injury. At least a moderate reduction in the intensity of attacks and the prevention of digital ulcers or tissue injury are achievable in most patients. However, abolishing cold sensitivity and eliminating all Raynaud events is not likely with available treatment options, particularly in patients with secondary RP, due to the complexity and sensitivity of the regulation of thermoregulatory vessels in the skin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23719?source=see_link\">",
"     \"Pathogenesis of the Raynaud phenomenon\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of the treatment depends upon the severity of disease and upon the presence or absence of an underlying disorder; this is particularly important in patients with an underlying systemic rheumatic disease related to systemic sclerosis (scleroderma), as such patients can have a structural component to their vascular disease in addition to the vasospastic component seen in all patients with RP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3061671\">",
"    <span class=\"h2\">",
"     Initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial treatment of patients with the Raynaud phenomenon is described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28200?source=see_link\">",
"     \"Initial treatment of the Raynaud phenomenon\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Briefly, such treatment includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient education and general nonpharmacologic measures in all patients for the prevention and treatment of RP. General measures include (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28200?source=see_link&amp;anchor=H2#H2\">",
"       \"Initial treatment of the Raynaud phenomenon\", section on 'Patient education'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28200?source=see_link&amp;anchor=H3#H3\">",
"       \"Initial treatment of the Raynaud phenomenon\", section on 'General measures'",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Avoiding cold exposure",
"     </li>",
"     <li>",
"      Maintaining whole body and digital warmth",
"     </li>",
"     <li>",
"      Smoking cessation",
"     </li>",
"     <li>",
"      Avoiding sympathomimetic medications and emotional stress",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment with calcium channel blockers in patients who do not respond adequately to general nonpharmacologic measures (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28200?source=see_link&amp;anchor=H188847410#H188847410\">",
"       \"Initial treatment of the Raynaud phenomenon\", section on 'General measures insufficient'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28200?source=see_link&amp;anchor=H188847417#H188847417\">",
"       \"Initial treatment of the Raynaud phenomenon\", section on 'Calcium channel blockers'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Behavioral interventions in selected patients (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28200?source=see_link&amp;anchor=H3057213#H3057213\">",
"       \"Initial treatment of the Raynaud phenomenon\", section on 'Behavioral therapy'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3061678\">",
"    <span class=\"h2\">",
"     Patients resistant to initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with the Raynaud phenomenon (RP) who do not respond adequately to initial therapies, further steps include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The addition or substitution of other pharmacologic agents, such as topical nitrates or phosphodiesterase 5 inhibitors, if calcium channel blockers (CCB) are insufficient (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Resistant to initial therapies'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H191749604\">",
"       'Combination of a CCB with other vasodilators'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Substitution of an alternative oral agent, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"       losartan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/16/23814?source=see_link\">",
"       prazosin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      , in patients with intolerance of CCBs (see",
"      <a class=\"local\" href=\"#H781713\">",
"       'Other alternatives to CCBs'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Treatment with an intravenous prostanoid, in patients with threatened or established digital ischemia that has not responded to oral or topical vasodilators (see",
"      <a class=\"local\" href=\"#H785246\">",
"       'Severe symptoms despite oral and topical agents'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H785742\">",
"       'Efficacy of parenteral prostaglandins and analogues'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Endothelin-1 receptor antagonist treatment in patients with digital ischemia and recurrent digital ulcers secondary to systemic sclerosis (scleroderma) (see",
"      <a class=\"local\" href=\"#H15565439\">",
"       'Recurrent digital ulcers in scleroderma'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Chemical sympathectomy, with a digital or regional block, used in patients with critical digital ischemia as a temporary measure prior to initiation of vasodilator therapy including intravenous prostanoids (see",
"      <a class=\"local\" href=\"#H786340\">",
"       'Chemical sympathectomy'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Surgical sympathectomy in patients failing medical therapy who have severe RP with digital ischemia (see",
"      <a class=\"local\" href=\"#H786347\">",
"       'Cervical sympathectomy'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H786354\">",
"       'Localized surgical digital sympathectomy'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Additional therapies, which may include anticoagulation, analgesics, antibiotics, and surgical debridement as clinically indicated (see",
"      <a class=\"local\" href=\"#H788523\">",
"       'Anticoagulation and antithrombotic therapy'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RESISTANT TO INITIAL THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients resistant to initial therapies, including general nonpharmacologic measures and maximum tolerated doses of calcium channel blockers (CCBs) known to be effective for the treatment of RP, we use the following measures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We review and reinforce the importance of continuing the general nonpharmacologic measures for prevention and treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28200?source=see_link&amp;anchor=H2#H2\">",
"       \"Initial treatment of the Raynaud phenomenon\", section on 'Patient education'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28200?source=see_link&amp;anchor=H3#H3\">",
"       \"Initial treatment of the Raynaud phenomenon\", section on 'General measures'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We revisit the underlying cause for the RP to readdress reversible causes or treatable aggravating or comorbid conditions.",
"     </li>",
"     <li>",
"      We add or substitute one of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A phosphodiesterase type-5 (PDE) inhibitor (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H782103\">",
"       'Phosphodiesterase type 5 inhibitors'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H782864\">",
"       'Topical nitrates'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Another oral alternative to CCBs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/16/23814?source=see_link\">",
"       prazosin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"       losartan",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H781713\">",
"       'Other alternatives to CCBs'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H191749604\">",
"    <span class=\"h2\">",
"     Combination of a CCB with other vasodilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who do not respond adequately to a calcium channel blocker (CCB) alone, we suggest the addition of either a phosphodiesterase (PDE) inhibitor (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    ) or another vasodilator. In patients in whom a PDE inhibitor is not available, effective, or well-tolerated, we suggest the use of topical nitrates. (See",
"    <a class=\"local\" href=\"#H782103\">",
"     'Phosphodiesterase type 5 inhibitors'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H782864\">",
"     'Topical nitrates'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Both classes of vasodilators have shown benefit in several randomized trials in patients with primary or secondary RP compared with placebo, but results have been mixed. Combination therapy of a CCB and another vasodilator has not been adequately evaluated in randomized trials but is increasingly being used in practice in difficult situations such as RP related to scleroderma with associated digital ulceration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H782103\">",
"    <span class=\"h3\">",
"     Phosphodiesterase type 5 inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who have obtained some but inadequate benefit from a CCB and who tolerate that therapy, we suggest the addition of a phosphodiesterase type 5 (PDE) inhibitor and continue the CCB. In patients who do not benefit from the CCB, we either add a PDE inhibitor or try the PDE inhibitor as an alternative, depending upon the ability to tolerate the medications, if critical ischemia is not present. (See",
"    <a class=\"local\" href=\"#H785246\">",
"     'Severe symptoms despite oral and topical agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Based upon the available evidence and our clinical experience, we initiate therapy at a low dose (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    20 mg once or twice daily) and increase the dose to 20 mg three times daily if no benefit is achieved. This dose is similar to that used in patients with pulmonary hypertension. A four- to six-week trial should be adequate to determine whether the combination is of benefit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26342?source=see_link&amp;anchor=H8#H8\">",
"     \"Pulmonary vascular disease in systemic sclerosis (scleroderma): Treatment\", section on 'Phosphodiesterase type 5 inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Care must be taken to fully assess cardiopulmonary status (eg, for pulmonary hypertension) before starting combined vasodilation therapy. Systemic blood pressure measurements should be followed serially. When possible, we advise patients to obtain a blood pressure (BP) cuff and to monitor their BP daily at first until dosing is stable and then weekly thereafter, as well as when symptoms of hypotension occur.",
"   </p>",
"   <p>",
"    A PDE inhibitor should not be used together with topical nitrates due to the increased risk of hypotension. Other adverse effects that may occur include peripheral edema, palpitations, tachycardia, hearing loss, and visual disturbances.",
"   </p>",
"   <p>",
"    The increasing use of these medications in efforts to improve peripheral and pulmonary circulation in several disorders is discussed in separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26342?source=see_link&amp;anchor=H8#H8\">",
"     \"Pulmonary vascular disease in systemic sclerosis (scleroderma): Treatment\", section on 'Phosphodiesterase type 5 inhibitors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/60/34762?source=see_link&amp;anchor=H38#H38\">",
"     \"Treatment of idiopathic pulmonary fibrosis\", section on 'Phosphodiesterase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H600793\">",
"    <span class=\"h4\">",
"     Efficacy of PDE inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several small trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    in patients with secondary RP have been reported, but results have been mixed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/1-12\">",
"     1-12",
"    </a>",
"    ]. Additional well-designed trials involving more patients are needed to better assess the role and optimal dosing of sildenafil, tadalafil, vardenafil, and other PDE inhibitors in primary and secondary RP. The following results illustrate the range of observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial that randomly assigned 20 patients with secondary RP to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      (50 mg twice daily) or to placebo noted significant improvements in mean attack rates and duration and in objective measures of nailfold capillary blood flow rates [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/7\">",
"       7",
"      </a>",
"      ]. However, subjects were able to tell active drug from placebo by the appearance of the pills, limiting the strength of these findings.",
"     </li>",
"     <li>",
"      A randomized four-week trial involving 57 patients with limited scleroderma showed a significant reduction in the frequency of attacks of RP using a modified-release form of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      (allowing once-daily dosing with 100 mg daily for three days and then 200 mg daily) compared with placebo (-44 versus -18 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/12\">",
"       12",
"      </a>",
"      ]. However, decreases from baseline in the Raynaud Condition Score, in duration of attacks, and in the Raynaud Phenomenon Pain Score did not differ significantly between groups. This form of sildenafil is not commercially available.",
"     </li>",
"     <li>",
"      One randomized crossover trial of 25 patients with scleroderma or mixed connective tissue disease with persistent episodes of RP despite the use of calcium channel blockers and other vasodilators found that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"       tadalafil",
"      </a>",
"      (20 mg on alternate days) was effective as add-on therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/1\">",
"       1",
"      </a>",
"      ]. Patients receiving tadalafil in addition to their other medications, compared with those receiving placebo, experienced a significantly greater frequency of healing of digital ulcers (24 of 24 lesions versus 3 of 13 lesions) and of preventing new ulcers (1 versus 13 new ulcers) without serious adverse events.",
"     </li>",
"     <li>",
"      A randomized four-week trial involving 39 patients with RP secondary to scleroderma found that treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"       tadalafil",
"      </a>",
"      (20 mg daily) resulted in no statistically significant differences compared with placebo in the Raynaud Condition Score or in the frequency and duration of RP episodes [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/6\">",
"       6",
"      </a>",
"      ]. The drug was well-tolerated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H782864\">",
"    <span class=\"h3\">",
"     Topical nitrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with an inadequate response to a calcium channel blocker (CCB) and for whom a phosphodiesterase inhibitor is not available, effective, or well-tolerated, we suggest the addition of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    (NTG), based upon benefit of various forms of topic nitrates in several randomized trials and in our clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/13-17\">",
"     13-17",
"    </a>",
"    ]. Nitrates have been used for the treatment of primary and secondary RP, with different methods of delivery including sustained-release transdermal patches, creams, gels, and ointments.",
"   </p>",
"   <p>",
"    We have found the topical nitrates to be more useful for patients with a single or small number of more severely affected digits and for short-term (days to weeks) use, compared with patients with more diffuse involvement and with the need for chronic (months to years) use. However, the efficacy of topical nitrates and duration of benefit are not well-defined, and significant side effects such as headache may occur with most forms of these agents.",
"   </p>",
"   <p>",
"    Topical NTG (eg, 0.5 inches [about 1.3 cm] of 2 percent ointment, approximately 15",
"    <span class=\"nowrap\">",
"     mg/inch",
"    </span>",
"    [38",
"    <span class=\"nowrap\">",
"     mg/cm])",
"    </span>",
"    should be applied to a single more severely affected or ischemic digit for 6 to 12 hours while continuing use of the CCB. The dose of topical NTG may vary depending upon the preparation and should be adjusted with close monitoring of tolerance and the clinical response. The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    2 percent ointment can be titrated as needed up to a full 2 inches (about 5.1 cm) every four to six hours with a 12-hour nitrate-free period. However, the higher dose is often not well-tolerated, and patients stop usage. The dose may be divided between several digits, although absorption with most preparations results in systemic effects. Preparations in development that are not available commercially may have reduced systemic absorption and fewer systemic adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/14,18\">",
"     14,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential side effects include headache, flushing, lightheadedness, decreased blood pressure, tachycardia, and aggravation of gastroesophageal reflux.",
"   </p>",
"   <p>",
"    In patients with low blood pressure, dehydration, acute or chronic heart failure, pulmonary hypertension, or ongoing use of a PDE inhibitor, topical nitrates should generally be avoided; they should be used with great caution and in low dose if essential for treatment for such patients.",
"   </p>",
"   <p>",
"    Several small observational studies and randomized trials of different topic nitrates have provided evidence for benefit in patients with RP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/13-17\">",
"     13-17",
"    </a>",
"    ]. The efficacy and tolerability of topical nitrates were evaluated in a randomized trial involving 219 patients with primary or secondary RP, in which application of a novel formulation of topical NTG provided benefit without significant adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/14\">",
"     14",
"    </a>",
"    ]. Topical NTG, MQX-503 (as a 0.5 gram aliquot of 0.9 percent gel), was applied before or within five minutes after the onset of an attack of RP, resulting in a statistically significant greater reduction in the Raynaud Condition Score (RCS), compared with use of a matching placebo gel (14.3 versus 1.3 percent). The RCS represents the level of difficulty experienced by the patient each day that is attributed to RP. This degree of improvement in the RCS is at the level reported to meet a minimally important difference [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/18\">",
"     18",
"    </a>",
"    ]. The frequency and duration of attacks and of side effects, including headache and dizziness, did not differ between groups. This preparation is not available commercially.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H781713\">",
"    <span class=\"h3\">",
"     Other alternatives to CCBs",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who do not reach the therapeutic goal or who are unable to tolerate a calcium channel blocker, a phosphodiesterase type-5 inhibitor, or a topical nitrate, alone or in combination, we use one of the other oral agents for which there is some, although very limited, evidence of benefit. Most studies of these agents do not provide solid evidence of efficacy due to small sample sizes, to limited duration of study, or to a lack of control data [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/17,19-21\">",
"     17,19-21",
"    </a>",
"    ]. These agents include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/16/23814?source=see_link\">",
"       Prazosin",
"      </a>",
"      , an &alpha;1-adrenergic receptor antagonist &mdash; In two small randomized trials, prazosin has been reported to improve RP [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. As an example, a blinded crossover study of 14 patients evaluated the effect of prazosin among patients with primary and secondary RP [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/22\">",
"       22",
"      </a>",
"      ]. Eight of nine patients with systemic lupus erythematosus, mixed connective tissue disease, or primary RP were clinically improved with active therapy. Only one of five patients with scleroderma reported improvement with prazosin. Patients will typically eventually become refractory to this agent after prolonged usage, in our experience.",
"      <br/>",
"      <br/>",
"      Other sympatholytic drugs in addition to prazosin have been used in RP including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"       methyldopa",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/35/16950?source=see_link\">",
"       reserpine",
"      </a>",
"      (which has been given intra-arterially) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/22-31\">",
"       22-31",
"      </a>",
"      ]. However, none of these agents is a specific inhibitor of the &alpha;2C-adrenergic receptor that is thought to be the major pathway through which cold-induced digital artery vasoconstriction is triggered. A laboratory based study using a specific &alpha;2C adrenergic receptor antagonist demonstrated improvement in cold-induced skin temperature suggesting that similar agents may be helpful in the treatment of RP, but a specific &alpha;2C agent is not available [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       Fluoxetine",
"      </a>",
"      , a selective serotonin reuptake inhibitor (SSRI) &mdash; Limited data suggest that SSRIs, primarily fluoxetine, may be of benefit for RP [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. The effects over six weeks of treatment with fluoxetine (20 mg daily) were compared with those of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      (40 mg daily) in an open-label crossover study involving 53 patients with primary and secondary RP; use of fluoxetine resulted in statistically significant reductions in the severity and frequency of attacks (by approximately 50 and 40 percent, respectively), but the decreases in severity and frequency of attacks with nifedipine (by approximately 25 to 30 percent and 15 to 20 percent, respectively) did not achieve statistical significance [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"       Losartan",
"      </a>",
"      , an angiotensin II receptor blocker &mdash; Losartan (50",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      resulted in a greater reduction in the severity and frequency of attacks in patients with primary RP and secondary (scleroderma-related) RP in a 12-week study in comparison with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      (40",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Angiotensin converting enzyme inhibitors &mdash; There is little evidence to suggest that angiotensin converting enzyme (ACE) inhibitors are effective for RP. Despite an open-label study that suggested some benefit from use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"       captopril",
"      </a>",
"      in patients with primary (but not secondary) RP, a subsequent randomized trial involving 210 patients with secondary RP did not support the use of an angiotensin converting enzyme (ACE) inhibitor for this indication [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. The trial found no evidence of benefit for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/29/24024?source=see_link\">",
"       quinapril",
"      </a>",
"      , an ACE inhibitor, in the incidence of digital ulcers or in the frequency or severity of attacks of RP [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several additional medications, which are used but for which there are very limited data to define clinical utility, include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The phosphodiesterase inhibitor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"       pentoxifylline",
"      </a>",
"      , which has been found to provide some benefit in a study of 11 patients with primary RP (including increased blood flow) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/38\">",
"       38",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Statins, which have been evaluated in an open-label study and a randomized trial for the treatment of scleroderma vascular disease [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. Preliminary studies using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      demonstrated reduced severity and frequency of Raynaud events, as well as reduction of ulcer formation, compared with placebo in patients with scleroderma. More studies are needed to define the role of statins in secondary Raynaud phenomenon. We limit the use of statins for RP to patients with scleroderma and recurrent digital ulcerations not responding to standard therapies and add it to other ongoing therapies. The rationale for the use of these agents includes their pleiotropic effects which may help protect the vasculature or prevent vascular events, including, in theory, their ability to inhibit the rho-kinase pathway, which regulates &alpha;2C adrenergic receptor expression [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antioxidant agents, such as zinc gluconate (50 to 150",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      which have also been utilized based upon the rationale that they may reduce tissue damage that may occur during ischemia-reperfusion from superoxide production [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/42-44\">",
"       42-44",
"      </a>",
"      ]. In one study, intravenous N-acetylcysteine reduced the frequency and severity of RP attacks compared with baseline and, in another uncontrolled study, reduced digital ulcers and severity of RP in scleroderma patients [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]. Probucol, a synthetic antioxidant, improved RP compared with a control group [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ginkgo biloba, an herbal medication that we do not use because the preponderance of evidence has not shown it to be beneficial [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/48,49\">",
"       48,49",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of other agents have been studied but failed to show adequate benefit or acceptable levels of safety compared with other available medications, including ketanserin, L-arginine, calcitonin gene-related peptide, and a thromboxane A2 inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/50-53\">",
"     50-53",
"    </a>",
"    ]. Other such agents include direct vasodilators, such as nitroprusside; hydralazine; papaverine; minoxidil; niacin; and topical agents, including nitric-oxide (via a generating system), hexyl nicotinate, and ethyl nicotinate [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/13,54\">",
"     13,54",
"    </a>",
"    ]. Sarpogrelate hydrochloride, a 5-hydroxytryptamine 2A serotonin receptor (5-HT2A) inhibitor available in Japan, has been reported to improve RP and to reduce digital ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/55-57\">",
"     55-57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H785246\">",
"    <span class=\"h1\">",
"     SEVERE SYMPTOMS DESPITE ORAL AND TOPICAL AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with threatened or established digital ischemia that has not responded to optimal therapy with oral or topical vasodilators, we suggest treatment with intravenous infusions of a prostaglandin, preferably a prostacyclin analogue, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"     iloprost",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/52/25414?source=see_link\">",
"     treprostinil",
"    </a>",
"    , depending upon availability (which varies between countries). The duration of such therapy is determined by the clinical outcome. Such patients may have severe symptoms that have a markedly adverse effect upon quality of life, or they may have digital ulcers or macrovascular events associated with RP that threaten digital loss.",
"   </p>",
"   <p>",
"    In countries where endothelin-1 antagonists have received regulatory approval for use in systemic sclerosis (scleroderma), use of these agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"     bosentan",
"    </a>",
"    ) for the prevention of new digital ulcers may precede use of intravenous prostaglandins in patients with scleroderma who do not require more urgent intervention. (See",
"    <a class=\"local\" href=\"#H15565439\">",
"     'Recurrent digital ulcers in scleroderma'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Some patients with severe symptoms of RP but without digital ulcers may prefer to avoid use of intravenous therapy. In some countries, such as the US, cost may be prohibitive for some patients due to lack of insurance coverage.",
"   </p>",
"   <p>",
"    Intravenous prostaglandin therapy is often administered in an inpatient setting, but hospitalization may not be required in uncomplicated, stable patients with an established diagnosis if an outpatient infusion center with monitoring is available. The latter approach is often utilized for administering",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"     iloprost",
"    </a>",
"    outside of the US.",
"   </p>",
"   <p>",
"    A careful review of ongoing vasodilator therapy should be undertaken prior to using intravenous prostaglandins (PG) to assure that the use of these first-line agents has been optimized, given the substantial inconvenience and potential cost of intravenous PG therapies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28200?source=see_link&amp;anchor=H188847417#H188847417\">",
"     \"Initial treatment of the Raynaud phenomenon\", section on 'Calcium channel blockers'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H3\">",
"     'Resistant to initial therapies'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H191749604\">",
"     'Combination of a CCB with other vasodilators'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The use of parenteral PG analogues for patients with severe digital ischemia is supported by multiple randomized trials and by systematic reviews and meta-analyses of such trials [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/21,58\">",
"     21,58",
"    </a>",
"    ]. The mechanisms of action may include potent vasodilatory effects, inhibition of platelet aggregation, and improvement of abnormal vascular reactivity. Parenteral (typically intravenous) administration of several PGs and PG analogues has been studied in the setting of severe digital ischemia. The use of oral PG analogues has been studied in primary and secondary RP, but there is insufficient evidence to support their use in clinical practice. (See",
"    <a class=\"local\" href=\"#H785742\">",
"     'Efficacy of parenteral prostaglandins and analogues'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H785749\">",
"     'Oral prostaglandins and analogs'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The options include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"       Iloprost",
"      </a>",
"      , infused at a rate of 0.5 to 2",
"      <span class=\"nowrap\">",
"       ng/kg",
"      </span>",
"      per minute through a peripheral intravenous line [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/59\">",
"       59",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"       Epoprostenol",
"      </a>",
"      , administered through a peripheral line, started at a dose of 2",
"      <span class=\"nowrap\">",
"       ng/kg",
"      </span>",
"      per minute, and increased over a period of one to two days, as tolerated, to 4 to 8",
"      <span class=\"nowrap\">",
"       ng/kg",
"      </span>",
"      per minute [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/60,61\">",
"       60,61",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/52/25414?source=see_link\">",
"       Treprostinil",
"      </a>",
"      , which may be given by subcutaneous injection or intravenously [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/62\">",
"       62",
"      </a>",
"      ]. However, in patients receiving the medication by subcutaneous injection, local pain at the injection site limits use in many patients, and its use in patients with severe symptoms of RP or critical ischemia by either the subcutaneous or intravenous route has not been reported.",
"     </li>",
"     <li>",
"      Alprostadil (PGE1), an alternative that has been administered at a dose of 6 to 10",
"      <span class=\"nowrap\">",
"       ng/kg",
"      </span>",
"      per minute through a central intravenous line [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/63\">",
"       63",
"      </a>",
"      ]. However, prostaglandin E1 has not been proven effective for treating RP [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/63-65\">",
"       63-65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Initial randomized trials with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"     iloprost",
"    </a>",
"    used a peripheral vein infusion at maximum rate of 2",
"    <span class=\"nowrap\">",
"     ng/kg/minute",
"    </span>",
"    for six hours each session for five days; the treatment group experienced significantly greater benefit compared with the placebo group over a nine-week follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/59\">",
"     59",
"    </a>",
"    ]. Based upon this experience, several weeks of improvement would be expected with this approach, justifying intermittent treatment during a problem period such as winter months. In an acute ischemic crisis, a rapid reversal of symptoms usually occurs. Side effects of therapy are usually reversible with a reduction in dose. The dose of intravenous prostaglandins should be adjusted to the level that is tolerated. (See",
"    <a class=\"local\" href=\"#H785742\">",
"     'Efficacy of parenteral prostaglandins and analogues'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Calcium channel blockers and other agents, such as topical nitrates or phosphodiesterase inhibitors, are continued in patients receiving a treatment course of intravenous prostaglandins (between infusions) but are generally not administered when patients are also receiving infusions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H785742\">",
"    <span class=\"h2\">",
"     Efficacy of parenteral prostaglandins and analogues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have examined the efficacy of treatment of severe refractory RP and ischemic digital ulcers with preparations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"     iloprost",
"    </a>",
"    (a PGI2 analog) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/59,66,67\">",
"     59,66,67",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    (a PGI2 analog) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/60,61\">",
"     60,61",
"    </a>",
"    ], and prostaglandin E1 (PGE1) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/63,64,68\">",
"     63,64,68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H787173\">",
"    <span class=\"h3\">",
"     Iloprost",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"     Iloprost",
"    </a>",
"    is an analog of prostacyclin (PGI2). Evidence of benefit for this agent in severe digital ischemia includes randomized trials and other studies that have employed varying doses and schedules for drug administration.",
"   </p>",
"   <p>",
"    A systematic review and meta-analysis involving 332 patients in seven randomized trials showed benefit in patients with secondary RP associated with scleroderma, with evidence for decreasing the severity and frequency of acute attacks and for preventing or healing digital ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/58\">",
"     58",
"    </a>",
"    ]. Dosing regimens in the trials varied. The effect was prolonged beyond the period of the infusion, and limited data suggested that the intravenous preparation was more effective than oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"     iloprost",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The range of findings and approaches are illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial involving 131 patients with secondary RP associated with scleroderma, which showed the efficacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"       iloprost",
"      </a>",
"      given intravenously (0.5 to 2",
"      <span class=\"nowrap\">",
"       ng/kg",
"      </span>",
"      per minute for six hours on five successive days) compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/59\">",
"       59",
"      </a>",
"      ]. Iloprost use resulted in short-term palliation of severe RP. The mean weekly attack rate and the Raynaud severity score both decreased in the patients treated with iloprost compared with those receiving placebo (39 and 35 percent versus 22 and 20 percent, respectively).",
"      <br/>",
"      <br/>",
"      Adverse events were seen in significantly more patients treated with iloprost compared with those receiving placebo (92 versus 57 percent). The most common side effects included headache (54 versus 21 percent), flushing (32 versus 6 percent), and nausea (29 versus 11 percent). Jaw pain, diarrhea, vomiting, injection site reactions, and myalgia were also common (5 to 15 percent versus 0 to 2 percent). The side effects were reversed by decreasing the dose of the iloprost and the rate of infusion. Hypotension and rashes may also occur. Withdrawal from the trial, usually for lack of benefit, was similar in the two groups (13 percent).",
"     </li>",
"     <li>",
"      A study that found short-term infusions of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"       iloprost",
"      </a>",
"      (for eight",
"      <span class=\"nowrap\">",
"       hours/day",
"      </span>",
"      on three consecutive days, with a repeat infusion for one day on week eight) comparably effective to oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      (up to 60",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      as tolerated for 16 weeks) in secondary RP associated with scleroderma [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/66\">",
"       66",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"       iloprost",
"      </a>",
"      in 30 patients with scleroderma with maintenance infusions every three weeks for a median of three years following an initial cycle of infusions over five days [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/69\">",
"       69",
"      </a>",
"      ]. Healing of digital ulcers and a subjective decrease RP were reported in this long-term uncontrolled study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H787290\">",
"    <span class=\"h3\">",
"     Other prostacyclins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostacyclin (PGI2) is also available for clinical use in some countries as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    (a PGI2 analogue), which has been most widely used for the treatment of idiopathic pulmonary hypertension and which has been used for pulmonary hypertension associated with scleroderma. Another prostacyclin analogue,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/52/25414?source=see_link\">",
"     treprostinil",
"    </a>",
"    , has been evaluated primarily as a subcutaneous injection but can be given via intravenous infusion. Inhaled prostacyclin (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"     iloprost",
"    </a>",
"    and treprostinil) is also available, but little experience is available to guide usage for RP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link\">",
"     \"Treatment of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence supporting use in patients with severe RP and digital ischemia includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small observational studies and randomized trials of PGI2 (prostacyclin) in RP, which showed benefit following intravenous infusion at the rate of 7.5 to 10",
"      <span class=\"nowrap\">",
"       ng/kg",
"      </span>",
"      per minute for three five-hour periods [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/60,61\">",
"       60,61",
"      </a>",
"      ]. The short-term benefit is similar to that reported with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"       iloprost",
"      </a>",
"      in our experience.",
"     </li>",
"     <li>",
"      Findings in a randomized trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"       epoprostenol",
"      </a>",
"      for pulmonary hypertension associated with scleroderma and related disorders, which showed a favorable but statistically nonsignificant difference in the severity of RP and fewer new digital ulcers in the epoprostenol treated patients [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/71\">",
"       71",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Improvement in digital ischemia and ulceration in patients with scleroderma who received subcutaneous infusions of a PGI2 analog (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/52/25414?source=see_link\">",
"       treprostinil",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/62,72\">",
"       62,72",
"      </a>",
"      ]. Unfortunately, many of the patients studied were unable to tolerate and continue receiving the medication due to severe injection site pain. Treprostinil can also be given intravenously.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H785749\">",
"    <span class=\"h2\">",
"     Oral prostaglandins and analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preparations of oral prostaglandins (PG) and analogues are available for study in Japan, Europe, and the United States, but further study, including randomized trials, will be required to establish the role of oral PGs in the management of severe RP. Mixed results have been obtained in studies evaluating their efficacy in RP.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study found that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      (an oral preparation of PGE1) did not reverse cold-induced vasospasm [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/73\">",
"       73",
"      </a>",
"      ]; however, another report found that limaprost (another oral PGEI analogue) increased peak digital blood velocity in patients with SLE and mixed connective disease (but not scleroderma) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cicaprost, a synthetic prostacyclin analogue, reduced the severity of the Raynaud phenomenon in one study [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Oral beraprost, another prostacyclin analogue, was no more beneficial than placebo in one study [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/76\">",
"       76",
"      </a>",
"      ], but a nonsignificant trend for benefit was observed in a second prospective report [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"       iloprost",
"      </a>",
"      was studied in two placebo-controlled trials of patients with scleroderma [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/78,79\">",
"       78,79",
"      </a>",
"      ]. Oral iloprost was no better than placebo for the management of RP. Use of inhaled iloprost has also been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/52/25414?source=see_link\">",
"       treprostinil",
"      </a>",
"      is under study for treatment of digital ulcers in patients with scleroderma. A preliminary report did not demonstrate benefit in preventing new ulcers or in improving healing [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15565439\">",
"    <span class=\"h1\">",
"     RECURRENT DIGITAL ULCERS IN SCLERODERMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with recurrent digital ulcers associated with systemic sclerosis (scleroderma) or related disorders and with continued or recurrent symptoms despite use of other therapies, including calcium channel blockers plus other agents and intravenous prostaglandins (PG), we suggest the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"     bosentan",
"    </a>",
"    , an orally administered inhibitor of the potent vasoconstrictor endothelin-1, based upon several randomized trials involving patients with scleroderma; these trials demonstrated a reduced frequency of new digital ulcers in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. Bosentan has been used primarily for the treatment of pulmonary hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link&amp;anchor=H26#H26\">",
"     \"Treatment of pulmonary hypertension in adults\", section on 'Bosentan'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26342?source=see_link&amp;anchor=H4#H4\">",
"     \"Pulmonary vascular disease in systemic sclerosis (scleroderma): Treatment\", section on 'Endothelin-1 receptor antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is inadequate evidence to indicate whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"     bosentan",
"    </a>",
"    should be used prior to intravenous (IV) PG to prevent recurrent digital ulcers in patients with scleroderma, although it has received regulatory approval in Europe for this indication. The choice of agents in this setting should be individualized. Some experts have greater experience with IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"     iloprost",
"    </a>",
"    , and there is greater risk of hepatotoxicity with bosentan, which requires close monitoring and which may be a particular concern in some patients. Clinician preference and experience with each treatment option, as well as patient preference regarding route of administration, frequency of outpatient monitoring, comorbidities, regulatory factors, and cost, may affect treatment choice.",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"     bosentan",
"    </a>",
"    is initiated at a dose of 62.5 mg twice daily for four weeks. The dose should be increased to 125 mg twice daily in patients who do not benefit from the initial dose. Liver function tests should be obtained monthly in patients receiving the medication to monitor for hepatic toxicity. The following trials illustrate the clinical benefits and limitations of bosentan:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial to directly examine its effect on recurrent digital ulcers in 122 patients with scleroderma noted a 50 percent reduction in new ulcers among those who had ulceration at baseline; however, there were no reduction in frequency or intensity of attacks of RP and no improvement in ulcer healing in patients with digital ulcers at baseline [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A subsequent trial in 188 patients with scleroderma with digital ulcers at trial entry found a statistically significant 30 percent reduction in new digital ulcers compared with placebo (1.9 versus 2.7) but also observed no differences in the healing rate of the cardinal ulcer [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/83\">",
"       83",
"      </a>",
"      ]. Peripheral edema and elevated aminotransferases were associated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"       bosentan",
"      </a>",
"      use. Further studies are needed to better define the role of bosentan or other endothelin antagonists in the treatment of secondary RP.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Commonly reported side effects are headache, flushing, edema (18 percent), hypotension, liver enzyme elevation (12 percent), and fatigue. Less common but more serious reactions include liver failure, bone marrow suppression, and angioedema. In the clinical trials, about 15 percent of patients discontinued therapy due to side effects. Selective endothelin-1 antagonists that are less toxic to the liver may have the potential of being helpful, but evidence regarding their use in this population is not available",
"   </p>",
"   <p>",
"    Evidence for the use of statins in scleroderma patients with recurrent digital ulcers is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]; however, a statin such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    can be used as an alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"     bosentan",
"    </a>",
"    if the latter agent is unavailable, is ineffective, or is poorly tolerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H785254\">",
"    <span class=\"h1\">",
"     DIGITAL ULCERATION WITH CRITICAL ISCHEMIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H790154\">",
"    <span class=\"h2\">",
"     Approach to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early intervention is very important in patients who develop digital ulcers with deeper tissue critical ischemia (eg, threatening loss of a portion of a digit); we take the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a demarcated ischemic digit secondary to larger vessel compromise should be hospitalized, should be kept warm and quiet, and should be fully evaluated for a secondary reversible process that is causing or aggravating the crisis. This includes a careful evaluation for correctable macrovascular disease, vasculitis, or an embolic or hypercoagulable state. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link\">",
"       \"Noninvasive diagnosis of arterial disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link\">",
"       \"Classification of and approach to the vasculitides in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pain due to severe ischemia may be intense, and adequate pain control may require the use of narcotic analgesics. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link\">",
"       \"Overview of the treatment of chronic pain\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40920?source=see_link\">",
"       \"Pain control in the critically ill adult patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients who are not receiving medical therapy for RP, we recommend starting a short-acting CCB, because of the urgency of intervention, as a vasodilator. We also suggest low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (75 to 81",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      as a component of the initial therapy in patients with scleroderma and acute digital ischemia, if there is no contraindication. However, there are inadequate studies to define the optimal approach to antiplatelet therapy in such patients. (See",
"      <a class=\"local\" href=\"#H785246\">",
"       'Severe symptoms despite oral and topical agents'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H788523\">",
"       'Anticoagulation and antithrombotic therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Based upon clinical experience, we suggest temporary chemical sympathectomy when oral",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      topical vasodilatory therapy does not quickly result in improvement in digital blood flow. This technique may provide relief while efforts are underway to obtain and prepare for administration of prostaglandins. If intravenous (IV) prostaglandins are readily available, such treatment is preferred to chemical or surgical sympathectomy. However, in some patients, chemical sympathectomy can lead to a reversal of symptoms that may be sustained, and prostaglandin infusions may not be required. (See",
"      <a class=\"local\" href=\"#H786340\">",
"       'Chemical sympathectomy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      We suggest treatment with IV prostaglandins (PG), as described for patients with severe symptoms of RP. An alternative preferred by some experts, especially if there is a lack of experience or of availability of IV PGs, is to proceed to surgical sympathectomy of the digit or hand rather than the IV therapy. (See",
"      <a class=\"local\" href=\"#H785246\">",
"       'Severe symptoms despite oral and topical agents'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H785742\">",
"       'Efficacy of parenteral prostaglandins and analogues'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H786333\">",
"       'Sympathectomy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Early intervention with thrombolytic therapy may be used in selected patients with a newly defined thrombotic or embolic event [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/84,85\">",
"       84,85",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H788523\">",
"       'Anticoagulation and antithrombotic therapy'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13368?source=see_link\">",
"       \"Acute arterial occlusion of the lower extremities (acute limb ischemia)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We advise the addition of either unfractionated or low molecular weight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      for a period of 24 to 72 hours if critical digital ischemia develops during vasodilator therapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      if the new onset of arterial occlusion is thought to be secondary to acute thrombosis or embolization. (See",
"      <a class=\"local\" href=\"#H788523\">",
"       'Anticoagulation and antithrombotic therapy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H786333\">",
"    <span class=\"h2\">",
"     Sympathectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with digital ulceration with critical ischemia, when oral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    topical vasodilatory therapy does not quickly result in improvement in digital blood flow and when IV prostaglandins are not readily available, we suggest, based upon clinical experience, that temporary chemical sympathectomy be performed with a digital or regional block. Chemical sympathectomy has not been systematically evaluated in clinical trials. We do not perform temporary cervical or lumbar sympathectomy because of the lack of evidence of lasting benefit. In addition, there is no evidence that a temporary sympathectomy will predict the degree of benefit of a permanent sympathectomy. Patients may also undergo either proximal or distal surgical sympathectomy. (See",
"    <a class=\"local\" href=\"#H786340\">",
"     'Chemical sympathectomy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H786347\">",
"     'Cervical sympathectomy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H786354\">",
"     'Localized surgical digital sympathectomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H786340\">",
"    <span class=\"h3\">",
"     Chemical sympathectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A temporary local chemical sympathectomy that can reverse vasoconstriction involves a digital or regional (eg, wrist) block with local infiltration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    (without epinephrine) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]; this procedure also relieves pain. Intra-digital and palmar botulinum toxin A has also been used for chemical sympathectomy.",
"   </p>",
"   <p>",
"    Temporary cervical or lumbar sympathectomy is rarely used unless other approaches have failed, because it does not have long-lasting benefit; however, sometimes it is temporarily effective in reversing acute vasospasm [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. Continuing medical therapy will hopefully maintain the improvement over time in patients treated with this approach.",
"   </p>",
"   <p>",
"    Intra-digital and palmar injection of botulinum toxin A was reported in uncontrolled studies to inhibit vasoconstriction, to relieve clinical symptoms, to improve skin blood flow, and to be associated with the healing of digital ulcers. These observations were in a pilot study of two patients and in several subsequent small case series involving patients with primary and secondary RP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/90-95\">",
"     90-95",
"    </a>",
"    ]. Randomized trials, greater experience, and a comparison with digital sympathectomy are needed to determine the relative efficacy and safety of this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H786347\">",
"    <span class=\"h3\">",
"     Cervical sympathectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several reports have suggested that cervical sympathectomy is helpful in primary RP but not in secondary forms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/96-99\">",
"     96-99",
"    </a>",
"    ]. However, these studies are generally more than 30 years old, are either individual cases or surveys, and have included patients with various causes of RP or different types of peripheral vascular disease. It is, therefore, difficult to draw any firm conclusion concerning the benefit of sympathectomy in RP. This procedure is associated with significant risks, including temporary or permanent Horner&rsquo;s syndrome, persistent neuralgia, and decreased localized cutaneous sweating. An endoscopic approach may be safer. For example, in one study of 28 patients treated using an endoscopic approach, no major complications occurred, and there were no intra- or perioperative deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is also unclear whether benefits that may occur with sympathectomy persist over time. An epidemiologic survey evaluated 140 patients with RP who had undergone sympathectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/101\">",
"     101",
"    </a>",
"    ]. Only 19 percent claimed lasting benefit, and 66 percent claimed no benefit after one year. However, another series of 25 patients with primary RP and 14 patients with secondary RP demonstrated long-lasting benefits with cervical sympathectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/102\">",
"     102",
"    </a>",
"    ]. The more recently developed endoscopic technique does not appear to have any advantage over the older open technique in terms of recurrent symptoms, as 82 percent of those who had initial relief of symptoms relapsed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/100,103\">",
"     100,103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sympathectomy is more likely to be helpful for patients with primary RP; however, these patients rarely need an aggressive surgical approach to therapy. Patients with secondary RP with critical ischemia or active digital ulcers are likely to have some immediate improvement in blood flow following sympathectomy, but the degree and duration of improvement are quite variable. Improvement may last for a relatively short time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H786354\">",
"    <span class=\"h3\">",
"     Localized surgical digital sympathectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Localized microsurgical digital sympathectomy has been introduced as an alternative to proximal sympathectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/104\">",
"     104",
"    </a>",
"    ]. Although a series of cases has reported successful results and few complications following digital sympathectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/105-109\">",
"     105-109",
"    </a>",
"    ], its exact role has not been defined by controlled investigations. A review noted that differences in surgical technique, in causes of digital ischemia, and in outcome measures made comparison of reported series difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/110\">",
"     110",
"    </a>",
"    ]. Amputation and recurrent ulceration following digital sympathectomy were frequent (14 and 18 percent, respectively). Among patients with scleroderma, RP, and digital ischemia, the perioperative complication rate was 37 percent. This procedure should be limited to patients who have failed medical treatment and who continue to have ischemia or severe RP which threatens the involved digit(s). When sympathectomy is decided as a necessary therapeutic option, we advise localized digital sympathectomy over proximal cervical or endoscopic procedures.",
"   </p>",
"   <p>",
"    We consider surgical sympathectomy only in patients with ischemia or severe RP which threatens viability of the involved digit(s) after vasodilator drugs have failed (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Resistant to initial therapies'",
"    </a>",
"    above) and after specific treatment for any reversible cause, such as vasculitis, has been administered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H788523\">",
"    <span class=\"h2\">",
"     Anticoagulation and antithrombotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple antithrombotic agents have been utilized in patients with RP in whom ulceration and thrombosis have occurred. These include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    , systemic anticoagulation, and thrombolytic therapy.",
"   </p>",
"   <p>",
"    The benefit of antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (75 or 81",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    is uncertain because of the lack of formal studies, but we suggest the use of low-dose aspirin in all patients with secondary RP who have a history of ischemic ulcers or other thrombotic events. Some clinicians recommend the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    because of its antiplatelet, vasodilating, and antioxidant properties, which may improve vascular tone. However, there is no formal experience with the use of dipyridamole or with the antiplatelet agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    for such complex cases of RP with digital ischemia.",
"   </p>",
"   <p>",
"    We use anticoagulation or thrombolytic therapy during the acute phase of an ischemic event in patients with embolic or vascular occlusive disease associated with new thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/111\">",
"     111",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anticoagulation with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      may be used for short periods during a crisis. Long-term therapy with low molecular weight heparin (LMWH) in a small placebo-controlled study was associated with a reduction in the severity of RP after 4 and 20 weeks of LMWH [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/112\">",
"       112",
"      </a>",
"      ]; further study of this approach is needed. However, patients with antiphospholipid antibodies with digital ischemia and RP may benefit from chronic anticoagulation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=see_link\">",
"       \"Treatment of the antiphospholipid syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thrombolytic therapy (eg, with tissue plasminogen activator) may be helpful in selected patients with RP and scleroderma [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/113\">",
"       113",
"      </a>",
"      ]. Early intervention in patients with a newly defined thrombotic or embolic event is required for it to be effective, and further trials will need to be performed to determine whether this approach will reverse acute ischemia in severe RP [",
"      <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/84,85\">",
"       84,85",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H788954\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraarterial or intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34485?source=see_link\">",
"     phentolamine",
"    </a>",
"    and intraarterial",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/35/16950?source=see_link\">",
"     reserpine",
"    </a>",
"    have been advocated for an acute ischemic event that is not responding to oral vasodilators or other measures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/28,30\">",
"     28,30",
"    </a>",
"    ]. However, there are few controlled data to provide guidance on their usage in this setting. In addition, the benefit of these and other sympatholytic agents tends to lessen with time, and these drugs often have intolerable side effects. There is no evidence that their use provides any advantage over that of a calcium channel blocker alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H786361\">",
"    <span class=\"h2\">",
"     Vascular reconstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful examination for larger vessel disease is recommended because occlusion of a major artery can occur in patients with secondary RP. Microsurgical revascularization of the hand and digital arterial reconstruction may improve digital vascular perfusion and may heal digital ulcers when proximal arterial occlusion is associated with digital vasospasm. As an example, in patients with scleroderma, arterial occlusion most commonly occurs in the ulnar artery and in the proper digital arteries. Revascularization of ulnar artery occlusive disease in this setting may improve RP and may improve healing of digital ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/30/28138/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/4/35905?source=see_link\">",
"       \"Patient information: Raynaud disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30481?source=see_link\">",
"       \"Patient information: Raynaud phenomenon (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who do not respond adequately to a calcium channel blocker (CCB) alone, we suggest the addition of a phosphodiesterase (PDE) inhibitor (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      ) rather than another orally administered vasodilator or topical nitrate (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Sildenafil is begun at 20 mg once or twice daily, while continuing the CCB if the latter agent has provided some benefit and is tolerated. (See",
"      <a class=\"local\" href=\"#H191749604\">",
"       'Combination of a CCB with other vasodilators'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H782103\">",
"       'Phosphodiesterase type 5 inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with an inadequate response to a CCB and for whom a PDE inhibitor is not available, effective, or well-tolerated, we suggest the addition of topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      (NTG) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Topical NTG (eg, 0.5 inches of 2 percent ointment, approximately 15",
"      <span class=\"nowrap\">",
"       mg/inch)",
"      </span>",
"      should be applied initially to a single more severely affected or ischemic digit for 6 to 12 hours while continuing use of the CCB. (See",
"      <a class=\"local\" href=\"#H782864\">",
"       'Topical nitrates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who do not reach the therapeutic goal or who are unable to tolerate a CCB, a PDE inhibitor, or a topical nitrate, either alone or in combination, alternative agents for which there is some limited evidence of benefit include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"       losartan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/16/23814?source=see_link\">",
"       prazosin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H781713\">",
"       'Other alternatives to CCBs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who receive optimal vasodilator therapy with first-line agents but who either have severe symptoms that have a markedly adverse effect upon quality of life or have digital ulcers or macrovascular events associated with RP that threaten digital loss, we suggest treatment with intravenous (IV) infusions of a prostaglandin (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). We prefer to use a prostacyclin analogue (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"       iloprost",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"       epoprostenol",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/52/25414?source=see_link\">",
"       treprostinil",
"      </a>",
"      ) depending upon availability. (See",
"      <a class=\"local\" href=\"#H785246\">",
"       'Severe symptoms despite oral and topical agents'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H785742\">",
"       'Efficacy of parenteral prostaglandins and analogues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with recurrent digital ulcers associated with scleroderma or related disorders and with continued or recurrent symptoms despite use of other therapies, including CCBs plus other agents and intravenous prostanoids, we suggest the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"       bosentan",
"      </a>",
"      , an orally administered endothelin-1 inhibitor, as the next step rather than other oral agents or sympathectomy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15565439\">",
"       'Recurrent digital ulcers in scleroderma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with a demarcated ischemic digit secondary to larger vessel compromise should be hospitalized, should be kept warm and quiet, should be provided adequate analgesia, and should be evaluated for a secondary reversible process that is causing or aggravating the crisis. Medical therapy with a CCB should be initiated in patients not receiving medical therapy. In patients with scleroderma and acute digital ischemia, if there is no contraindication, we suggest antiplatelet therapy with low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (75 to 81",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      as a component of the initial treatment program (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H785254\">",
"       'Digital ulceration with critical ischemia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H790154\">",
"       'Approach to treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with digital ulceration with critical ischemia, when oral",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      topical vasodilatory therapy does not quickly result in improvement in digital blood flow and when IV prostaglandins are not readily available, we suggest that temporary chemical sympathectomy be performed using a digital or regional (wrist) block with local infiltration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"       bupivacaine",
"      </a>",
"      (without epinephrine) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients may also undergo either proximal or distal surgical sympathectomy. (See",
"      <a class=\"local\" href=\"#H786340\">",
"       'Chemical sympathectomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H786347\">",
"       'Cervical sympathectomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H786354\">",
"       'Localized surgical digital sympathectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest antiplatelet therapy with low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (75 or 81",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      in all patients with secondary RP who have a history of ischemic ulcers or other thrombotic events (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Dipyramidole or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      are alternative agents that may be used in this setting. We use anticoagulation or thrombolytic therapy during the acute phase of an ischemic event in patients with embolic or vascular occlusive disease associated with new thrombosis. (See",
"      <a class=\"local\" href=\"#H788523\">",
"       'Anticoagulation and antithrombotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/1\">",
"      Shenoy PD, Kumar S, Jha LK, et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology (Oxford) 2010; 49:2420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/2\">",
"      Lichtenstein JR. Use of sildenafil citrate in Raynaud's phenomenon: comment on the article by Thompson et al. Arthritis Rheum 2003; 48:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/3\">",
"      Kumana CR, Cheung GT, Lau CS. Severe digital ischaemia treated with phosphodiesterase inhibitors. Ann Rheum Dis 2004; 63:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/4\">",
"      Gore J, Silver R. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis. Ann Rheum Dis 2005; 64:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/5\">",
"      Kamata Y, Kamimura T, Iwamoto M, Minota S. Comparable effects of sildenafil citrate and alprostadil on severe Raynaud's phenomenon in a patient with systemic sclerosis. Clin Exp Dermatol 2005; 30:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/6\">",
"      Schiopu E, Hsu VM, Impens AJ, et al. Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. J Rheumatol 2009; 36:2264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/7\">",
"      Fries R, Shariat K, von Wilmowsky H, B&ouml;hm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 2005; 112:2980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/8\">",
"      Caglayan E, Huntgeburth M, Karasch T, et al. Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Intern Med 2006; 166:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/9\">",
"      Friedman EA, Harris PA, Wood AJ, et al. The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud's phenomenon. Clin Pharmacol Ther 2007; 81:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/10\">",
"      De LaVega AJ, Derk CT. Phosphodiesterase-5 inhibitors for the treatment of Raynaud's: a novel indication. Expert Opin Investig Drugs 2009; 18:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/11\">",
"      Brueckner CS, Becker MO, Kroencke T, et al. Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann Rheum Dis 2010; 69:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/12\">",
"      Herrick AL, van den Hoogen F, Gabrielli A, et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum 2011; 63:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/13\">",
"      Tucker AT, Pearson RM, Cooke ED, Benjamin N. Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynaud's syndrome: a randomised trial. Lancet 1999; 354:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/14\">",
"      Chung L, Shapiro L, Fiorentino D, et al. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial. Arthritis Rheum 2009; 60:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/15\">",
"      Kan C, Akimoto S, Abe M, et al. Preliminary thermographic evaluation of new nitroglycerine tape on the peripheral circulatory disturbance in systemic sclerosis. Ann Rheum Dis 2002; 61:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/16\">",
"      Teh LS, Manning J, Moore T, et al. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon. Br J Rheumatol 1995; 34:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/17\">",
"      Herrick AL. Contemporary management of Raynaud's phenomenon and digital ischaemic complications. Curr Opin Rheumatol 2011; 23:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/18\">",
"      Khanna PP, Maranian P, Gregory J, Khanna D. The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial. Ann Rheum Dis 2010; 69:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/19\">",
"      Henness S, Wigley FM. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review. Curr Opin Rheumatol 2007; 19:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/20\">",
"      Vinjar B, Stewart M. Oral vasodilators for primary Raynaud's phenomenon. Cochrane Database Syst Rev 2008; :CD006687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/21\">",
"      Huisstede BM, Hoogvliet P, Paulis WD, et al. Effectiveness of interventions for secondary Raynaud's phenomenon: a systematic review. Arch Phys Med Rehabil 2011; 92:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/22\">",
"      Russell IJ, Lessard JA. Prazosin treatment of Raynaud's phenomenon: a double blind single crossover study. J Rheumatol 1985; 12:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/23\">",
"      Wollersheim H, Thien T, Fennis J, et al. Double-blind, placebo-controlled study of prazosin in Raynaud's phenomenon. Clin Pharmacol Ther 1986; 40:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/24\">",
"      LeRoy EC, Downey JA, Cannon PJ. Skin capillary blood flow in scleroderma. J Clin Invest 1971; 50:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/25\">",
"      Robson P, Pearce V, Antcliff AC, Hamilton M. Double-blind trial of indoramin in digital artery disease. Br J Clin Pharmacol 1978; 6:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/26\">",
"      Varadi DP, Lawrence AM. Suppression of Raynaud's phenomenon by methyldopa. Arch Intern Med 1969; 124:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/27\">",
"      Russell IJ, Walsh RA. Selection of vasodilator therapy for severe Raynaud's phenomenon by sequential arterial infusion. Ann Rheum Dis 1985; 44:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/28\">",
"      Coffman JD, Cohen RA. Intra-arterial vasodilator agents to reverse human finger vasoconstriction. Clin Pharmacol Ther 1987; 41:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/29\">",
"      Willerson JT, Thompson RH, Hookman P, et al. Reserpine in Raynaud's disease and phenomenon. Short-term response to intra-arterial injection. Ann Intern Med 1970; 72:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/30\">",
"      McFadyen IJ, Housley E, MacPherson AI. Intraarterial reserpine administration in Raynaud syndrome. Arch Intern Med 1973; 132:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/31\">",
"      PRANDONI AG, MOSER M. Clinical appraisal of intra-arterial priscoline therapy in the management of peripheral arterial diseases. Circulation 1954; 9:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/32\">",
"      Wise RA, Wigley FM, White B, et al. Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study. Arthritis Rheum 2004; 50:3994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/33\">",
"      Jaffe IA. Serotonin reuptake inhibitors in Raynaud's phenomenon. Lancet 1995; 345:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/34\">",
"      Coleiro B, Marshall SE, Denton CP, et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 2001; 40:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/35\">",
"      Dziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999; 42:2646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/36\">",
"      Gliddon AE, Dor&eacute; CJ, Black CM, et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum 2007; 56:3837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/37\">",
"      Tosi S, Marchesoni A, Messina K, et al. Treatment of Raynaud's phenomenon with captopril. Drugs Exp Clin Res 1987; 13:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/38\">",
"      Neirotti M, Longo F, Molaschi M, et al. Functional vascular disorders: treatment with pentoxifylline. Angiology 1987; 38:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/39\">",
"      Abou-Raya A, Abou-Raya S, Helmii M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. J Rheumatol 2008; 35:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/40\">",
"      Kuwana M, Okazaki Y, Kaburaki J. Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis. Mod Rheumatol 2009; 19:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/41\">",
"      Kuwana M. Potential benefit of statins for vascular disease in systemic sclerosis. Curr Opin Rheumatol 2006; 18:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/42\">",
"      Mariani E, Mangialasche F, Feliziani FT, et al. Effects of zinc supplementation on antioxidant enzyme activities in healthy old subjects. Exp Gerontol 2008; 43:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/43\">",
"      Al-Sheikh YA, Ghneim HK. 'The effect of micronutrients on superoxide dismutase in senescent fibroblasts'. Cell Biochem Funct 2011; 29:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/44\">",
"      Eby GA, Halcomb WW. High-dose zinc to terminate angina pectoris: a review and hypothesis for action by ICAM inhibition. Med Hypotheses 2006; 66:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/45\">",
"      Sambo P, Amico D, Giacomelli R, et al. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study. J Rheumatol 2001; 28:2257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/46\">",
"      Rosato E, Borghese F, Pisarri S, Salsano F. The treatment with N-acetylcysteine of Raynaud's phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients. Clin Rheumatol 2009; 28:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/47\">",
"      Denton CP, Bunce TD, Dorado MB, et al. Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon. Rheumatology (Oxford) 1999; 38:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/48\">",
"      Muir AH, Robb R, McLaren M, et al. The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo-controlled trial. Vasc Med 2002; 7:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/49\">",
"      Bredie SJ, Jong MC. No significant effect of ginkgo biloba special extract EGb 761 in the treatment of primary Raynaud phenomenon: a randomized controlled trial. J Cardiovasc Pharmacol 2012; 59:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/50\">",
"      Coffman JD, Clement DL, Creager MA, et al. International study of ketanserin in Raynaud's phenomenon. Am J Med 1989; 87:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/51\">",
"      Khan F, Litchfield SJ, McLaren M, et al. Oral L-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon. Arthritis Rheum 1997; 40:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/52\">",
"      Bunker CB, Reavley C, O'Shaughnessy DJ, Dowd PM. Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenon. Lancet 1993; 342:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/53\">",
"      Ettinger WH, Wise RA, Schaffhauser D, Wigley FM. Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. Am J Med 1984; 77:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/54\">",
"      Bowling JC, Dowd PM. Raynaud's disease. Lancet 2003; 361:2078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/55\">",
"      Kumagai S, Morinobu A, Ozaki S, et al. [Sarpogrelate hydrochloride for Raynaud's phenomenon of patients with collagen diseases]. Ryumachi 1998; 38:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/56\">",
"      Kato S, Kishiro I, Ohnuma N, et al. Suppressive effect of saprogrelate hydrochloride on Raynaud's phenomenon and respiratory failure in patients with systemic sclerosis. Respirology 2000; 5:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/57\">",
"      Yoshimasu T, Ikeda T, Uede K, et al. Effects of sarpogrelate hydrochloride on skin ulcers and quality of life in patients with systemic sclerosis. J Dermatol 2012; 39:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/58\">",
"      Pope J, Fenlon D, Thompson A, et al. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2000; :CD000953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/59\">",
"      Wigley FM, Wise RA, Seibold JR, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994; 120:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/60\">",
"      Dowd PM, Martin MF, Cooke ED, et al. Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2). Br J Dermatol 1982; 106:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/61\">",
"      Belch JJ, Newman P, Drury JK, et al. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial. Lancet 1983; 1:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/62\">",
"      Chung L, Fiorentino D. A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis. J Am Acad Dermatol 2006; 54:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/63\">",
"      Clifford PC, Martin MF, Sheddon EJ, et al. Treatment of vasospastic disease with prostaglandin E1. Br Med J 1980; 281:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/64\">",
"      Mohrland JS, Porter JM, Smith EA, et al. A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's syndrome. Ann Rheum Dis 1985; 44:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/65\">",
"      Gardinali M, Pozzi MR, Bernareggi M, et al. Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis. J Rheumatol 2001; 28:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/66\">",
"      Rademaker M, Cooke ED, Almond NE, et al. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. BMJ 1989; 298:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/67\">",
"      Kyle MV, Belcher G, Hazleman BL. Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon. J Rheumatol 1992; 19:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/68\">",
"      Langevitz P, Buskila D, Lee P, Urowitz MB. Treatment of refractory ischemic skin ulcers in patients with Raynaud's phenomenon with PGE1 infusions. J Rheumatol 1989; 16:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/69\">",
"      Bettoni L, Geri A, Air&ograve; P, et al. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. Clin Rheumatol 2002; 21:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/70\">",
"      Pakozdi A, Howell K, Wilson H, et al. Inhaled iloprost for the treatment of Raynaud's phenomenon. Clin Exp Rheumatol 2008; 26:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/71\">",
"      Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/72\">",
"      Engel G, Rockson SG. Treprostinil for the treatment of severe digital necrosis in systemic sclerosis. Vasc Med 2005; 10:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/73\">",
"      Wise RA, Wigley F. Acute effects of misoprostol on digital circulation in patients with Raynaud's phenomenon. J Rheumatol 1994; 21:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/74\">",
"      Tsukamoto H, Nagasawa K. Successful treatment of Raynaud's phenomenon with limaprost, an oral prostaglandin E1 analogue. Br J Rheumatol 1991; 30:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/75\">",
"      Lau CS, Belch JJ, Madhok R, et al. A randomised, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's phenomenon secondary to systemic sclerosis. Clin Exp Rheumatol 1993; 11:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/76\">",
"      Vayssairat M. Controlled multicenter double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud's phenomenon. French Microcirculation Society Multicentre Group for the Study of Vascular Acrosyndromes. J Rheumatol 1996; 23:1917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/77\">",
"      Vayssairat M. Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis. French Microcirculation Society Multicenter Group for the Study of Vascular Acrosyndromes. J Rheumatol 1999; 26:2173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/78\">",
"      Belch JJ, Capell HA, Cooke ED, et al. Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study. Ann Rheum Dis 1995; 54:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/79\">",
"      Wigley FM, Korn JH, Csuka ME, et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum 1998; 41:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/80\">",
"      Seibold JR, Wigley FM, Schiopu E, et al. Digital ischemic ulcers in scleroderma treated with oral treprostinil diethanolamine: A randomized, double-blind, placebo-controlled, multicenter study. Arthritis Rheum 2011; 63:S968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/81\">",
"      Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/82\">",
"      Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 50:3985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/83\">",
"      Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011; 70:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/84\">",
"      Bridges AJ, Spadone DP. Tissue plasminogen activator treatment of digital thrombosis in severe Raynaud's phenomenon--a case report. Angiology 1993; 44:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/85\">",
"      Lakshminarayanan S, V&aacute;zquez-Abad D, Maestrello SJ, Waterman JR. Treatment of severe Raynaud's phenomenon and ischemic ulcerations with tissue plasimogen activator. Clin Exp Rheumatol 1999; 17:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/86\">",
"      Wigley FM. Clinical practice. Raynaud's Phenomenon. N Engl J Med 2002; 347:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/87\">",
"      Engelhart M. The effect of sympathetic blockade and cooling in Raynaud's phenomenon. Clin Physiol 1990; 10:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/88\">",
"      Setacci C, de Donato G, Teraa M, et al. Chapter IV: Treatment of critical limb ischaemia. Eur J Vasc Endovasc Surg 2011; 42 Suppl 2:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/89\">",
"      Greengrass RA, Feinglass NG, Murray PM, Trigg SD. Continuous regional anesthesia before surgical peripheral sympathectomy in a patient with severe digital necrosis associated with Raynaud's phenomenon and scleroderma. Reg Anesth Pain Med 2003; 28:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/90\">",
"      Sycha T, Graninger M, Auff E, Schnider P. Botulinum toxin in the treatment of Raynaud's phenomenon: a pilot study. Eur J Clin Invest 2004; 34:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/91\">",
"      Van Beek AL, Lim PK, Gear AJ, Pritzker MR. Management of vasospastic disorders with botulinum toxin A. Plast Reconstr Surg 2007; 119:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/92\">",
"      Neumeister MW, Chambers CB, Herron MS, et al. Botox therapy for ischemic digits. Plast Reconstr Surg 2009; 124:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/93\">",
"      Iorio ML, Masden DL, Higgins JP. Botulinum toxin A treatment of Raynaud's phenomenon: a review. Semin Arthritis Rheum 2012; 41:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/94\">",
"      Neumeister MW. Botulinum toxin type A in the treatment of Raynaud's phenomenon. J Hand Surg Am 2010; 35:2085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/95\">",
"      Fregene A, Ditmars D, Siddiqui A. Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud's phenomenon. J Hand Surg Am 2009; 34:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/96\">",
"      GIFFORD RW Jr, HINES EA Jr, CRAIG WM. Sympathectomy for Raynaud's phenomenon; follow-up study of 70 women with Raynaud's disease and 54 women with secondary Raynaud's phenomenon. Circulation 1958; 17:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/97\">",
"      JOHNSTON EN, SUMMERLY R, BIRNSTINGL M. PROGNOSIS IN RAYNAUD'S PHENOMENON AFTER SYMPATHECTOMY. Br Med J 1965; 1:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/98\">",
"      DE TAKATS G, FOWLER EF. Raynaud's phenomenon. JAMA 1962; 179:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/99\">",
"      Montorsi W, Ghiringhelli C, Annoni F. Indications and results of the surgical treatment in Raynaud's phenomenon. J Cardiovasc Surg (Torino) 1980; 21:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/100\">",
"      Matsumoto Y, Ueyama T, Endo M, et al. Endoscopic thoracic sympathicotomy for Raynaud's phenomenon. J Vasc Surg 2002; 36:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/101\">",
"      de Trafford JC, Lafferty K, Potter CE, et al. An epidemiological survey of Raynaud's phenomenon. Eur J Vasc Surg 1988; 2:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/102\">",
"      van de Wal HJ, Skotnicki SH, Wijn PF, Lacquet LK. Thoracic sympathectomy as a therapy for upper extremity ischemia. A long-term follow-up study. Thorac Cardiovasc Surg 1985; 33:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/103\">",
"      Thune TH, Ladegaard L, Licht PB. Thoracoscopic sympathectomy for Raynaud's phenomenon--a long term follow-up study. Eur J Vasc Endovasc Surg 2006; 32:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/104\">",
"      Flatt AE. Digital artery sympathectomy. J Hand Surg Am 1980; 5:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/105\">",
"      Egloff DV, Mifsud RP, Verdan C. Superselective digital sympathectomy in Raynaud's phenomenon. Hand 1983; 15:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/106\">",
"      Wilgis EF. Evaluation and treatment of chronic digital ischemia. Ann Surg 1981; 193:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/107\">",
"      Drake DB, Kesler RW, Morgan RF. Digital sympathectomy for refractory Raynaud's phenomenon in an adolescent. J Rheumatol 1992; 19:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/108\">",
"      Yee AM, Hotchkiss RN, Paget SA. Adventitial stripping: a digit saving procedure in refractory Raynaud's phenomenon. J Rheumatol 1998; 25:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/109\">",
"      Tomaino MM, Goitz RJ, Medsger TA. Surgery for ischemic pain and Raynaud's' phenomenon in scleroderma: a description of treatment protocol and evaluation of results. Microsurgery 2001; 21:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/110\">",
"      Wasserman A, Brahn E. Systemic sclerosis: bilateral improvement of Raynaud's phenomenon with unilateral digital sympathectomy. Semin Arthritis Rheum 2010; 40:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/111\">",
"      Clagett GP, Sobel M, Jackson MR, et al. Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:609S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/112\">",
"      Denton CP, Howell K, Stratton RJ, Black CM. Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study. Clin Exp Rheumatol 2000; 18:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/113\">",
"      Hart DA, Fritzler MJ. Regulation of plasminogen activators and their inhibitors in rheumatic diseases: new understanding and the potential for new directions. J Rheumatol 1989; 16:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/30/28138/abstract/114\">",
"      Taylor MH, McFadden JA, Bolster MB, Silver RM. Ulnar artery involvement in systemic sclerosis (scleroderma). J Rheumatol 2002; 29:102.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7552 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"footerNav\">",
"   <ul>",
"    <li>",
"     <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Wolters Kluwer Health",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Facts &amp; Comparisons&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"      Medi-Span&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Order Sets",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Medical",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Pharmacy OneSource&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"      Medicom",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Lexicomp",
"     </a>",
"    </li>",
"    <li class=\"last\">",
"     <a href=\"/home/privacy-policy\">",
"      Privacy Policy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <div id=\"footerLogo\">",
"   <a href=\"./toc\">",
"    Wolters Kluwer Health | UpToDate",
"   </a>",
"  </div>",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"sfInfo\">",
"    <a href=\"/home/terms-use\">",
"     Terms of Use",
"    </a>",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     UpToDate Marketing Professional",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-95.86.206.209-C5E277D347-14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_30_28138=[""].join("\n");
var outline_f27_30_28138=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3060071\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3060078\">",
"      PRIMARY AND SECONDARY RP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3060085\">",
"      GOALS AND OVERVIEW OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3061671\">",
"      Initial therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3061678\">",
"      Patients resistant to initial therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RESISTANT TO INITIAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H191749604\">",
"      Combination of a CCB with other vasodilators",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H782103\">",
"      - Phosphodiesterase type 5 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H600793\">",
"      Efficacy of PDE inhibition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H782864\">",
"      - Topical nitrates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H781713\">",
"      - Other alternatives to CCBs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H785246\">",
"      SEVERE SYMPTOMS DESPITE ORAL AND TOPICAL AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H785742\">",
"      Efficacy of parenteral prostaglandins and analogues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H787173\">",
"      - Iloprost",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H787290\">",
"      - Other prostacyclins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H785749\">",
"      Oral prostaglandins and analogs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15565439\">",
"      RECURRENT DIGITAL ULCERS IN SCLERODERMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H785254\">",
"      DIGITAL ULCERATION WITH CRITICAL ISCHEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H790154\">",
"      Approach to treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H786333\">",
"      Sympathectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H786340\">",
"      - Chemical sympathectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H786347\">",
"      - Cervical sympathectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H786354\">",
"      - Localized surgical digital sympathectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H788523\">",
"      Anticoagulation and antithrombotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H788954\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H786361\">",
"      Vascular reconstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13368?source=related_link\">",
"      Acute arterial occlusion of the lower extremities (acute limb ischemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=related_link\">",
"      Classification of and approach to the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=related_link\">",
"      Clinical manifestations and diagnosis of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28200?source=related_link\">",
"      Initial treatment of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=related_link\">",
"      Noninvasive diagnosis of arterial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=related_link\">",
"      Overview of the treatment of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40920?source=related_link\">",
"      Pain control in the critically ill adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23719?source=related_link\">",
"      Pathogenesis of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/4/35905?source=related_link\">",
"      Patient information: Raynaud disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30481?source=related_link\">",
"      Patient information: Raynaud phenomenon (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26342?source=related_link\">",
"      Pulmonary vascular disease in systemic sclerosis (scleroderma): Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/60/34762?source=related_link\">",
"      Treatment of idiopathic pulmonary fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=related_link\">",
"      Treatment of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=related_link\">",
"      Treatment of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_30_28139="Diffuse lung disease diagnosis";
var content_f27_30_28139=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54536&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54536&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Radiographic approach to the diagnosis of diffuse lung disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Analysis of predominant opacities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shape",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Profusion (number of opacities per unit area)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zonal predilection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Analysis of lung volumes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Small",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Large",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Distribution of disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Upper zone disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Basal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Associated findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pleura",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hilar regions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mediastinum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heart",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary vasculature",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_30_28139=[""].join("\n");
var outline_f27_30_28139=null;
var title_f27_30_28140="Nonstandardized allergens - Effective doses";
var content_f27_30_28140=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F69763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F69763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    US nonstandardized extracts: Effective and ineffective doses and major allergen content",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Allergen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effective doses*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ineffective doses*",
"       </td>",
"       <td class=\"subtitle1\">",
"        US nonstandardized extracts",
"       </td>",
"       <td class=\"subtitle1\">",
"        Average major allergen content",
"        <span class=\"small\">",
"         &bull;",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dog (acetone precipitated)",
"       </td>",
"       <td>",
"        15 mcg Can f 1",
"       </td>",
"       <td>",
"        3 mcg Can f 1",
"       </td>",
"       <td>",
"        1:100 w/v",
"       </td>",
"       <td>",
"        140 mcg/mL Can f 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dog (aqueous)",
"       </td>",
"       <td>",
"        15 mcg Can f 1",
"       </td>",
"       <td>",
"        3 mcg Can f 1",
"       </td>",
"       <td>",
"        1:10 w/v",
"       </td>",
"       <td>",
"        5 mcg/mL Can f 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Birch",
"       </td>",
"       <td>",
"        3.25 to 12 mcg Bet v 1",
"       </td>",
"       <td>",
"        Not determined",
"       </td>",
"       <td>",
"        1:10 w/v",
"       </td>",
"       <td>",
"        390 mcg/mL Bet v 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Olive",
"       </td>",
"       <td>",
"        Not determined",
"       </td>",
"       <td>",
"        Not determined",
"       </td>",
"       <td>",
"        1:10 w/v",
"       </td>",
"       <td>",
"        430 mcg/mL Ole e 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sagebrush",
"       </td>",
"       <td>",
"        Not determined",
"       </td>",
"       <td>",
"        Not determined",
"       </td>",
"       <td>",
"        1:10 w/v",
"       </td>",
"       <td>",
"        1300 mcg/mL Art v 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Alternaria alternata",
"        </em>",
"       </td>",
"       <td>",
"        1.6 mcg Alt a 1",
"       </td>",
"       <td>",
"        Not determined",
"       </td>",
"       <td>",
"        1:20 w/v",
"       </td>",
"       <td>",
"        &lt;0.01 to 6.1 mcg/mL Alt a 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Aspergillus fumigatus",
"        </em>",
"       </td>",
"       <td>",
"        Not determined",
"       </td>",
"       <td>",
"        Not determined",
"       </td>",
"       <td>",
"        1:20 w/v",
"       </td>",
"       <td>",
"        &lt;0.01 to 64 mcg/mL Asp f 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        German cockroach",
"       </td>",
"       <td>",
"        Not determined",
"       </td>",
"       <td>",
"        Not determined",
"       </td>",
"       <td>",
"        1:20 w/v",
"       </td>",
"       <td>",
"        8 to 66 mcg/mL Bla g 2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     w/v: weight/volume.",
"     <br>",
"      * Effective and ineffective doses are based upon double-blind, placebo-controlled studies.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Mean values; individual lots of extracts may vary considerably from these values.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_30_28140=[""].join("\n");
var outline_f27_30_28140=null;
var title_f27_30_28141="LVEF survival LV dysfunction";
var content_f27_30_28141=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mortality in heart failure is related to left ventricular function",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 306px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier survival curves of 1172 patients in the SOLVD trials and registry show that a left ventricular ejection fraction (LVEF) &lt;35 percent is associated with an increased all-cause mortality (risk ratio 1.8 compared to a LVEF &ge;35 percent, p = 0.012).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Quinones MA, Greenberg BH, Kopelen HA, et al, for the SOLVD Investigators. J Am Coll Cardiol 2000; 35:1237.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_30_28141=[""].join("\n");
var outline_f27_30_28141=null;
var title_f27_30_28142="Hood silicone stent studded";
var content_f27_30_28142=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66659&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66659&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Studded hood silicone stent",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 428px; height: 238px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADuAawDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACilVSzAKCSegFdPofgLxLrRjNlpNyYnP+tZdqgepzSbS3Buxy9Fe36Z8DVjiDa5rSRv3jtAHI/Op7n4X+FrJCTfX8xHZlUZ/KsnXhsiHUijwmlAJOB1r3K00HQ9Kk32eno8o43Skt+hqy07D/AFdraADoBbpn+VP2jeyMniF0R4nDoupzJuh0+6dfVYmI/lVy38Ka7OcJpV2P96Ir/OvXUlvGYbQyAnPB2j8hWjbS6gWy10yAc43E1Eqkl2D2z7Hjh8CeJNpYaXOQPRc1Sl8La9ET5mj364/6YN/hX0nYTzRokv2qViRySeK6PTWN3Dve4xg4YM361g8TOKvozSM7uzPje6s7m0YLdQSwsegdSv8AOq9fYus21rMklvNb2twpGAxiU/rivJPHvwvWeyk1Tw1FIbvf+9sABjaf4kP8xVQxsXbn0NUm3ZHitFXL7TbywkKXltLC4OMMtU67E09UIKKKKYBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRVzTtMvtTkMen2s1y46rGpY0N23A9U/Z3/sEazcnULVLrWRg2iyjKqO7KP739K+gkuWuZHMqjzPcYyPwr5j+HPg3X08Y6dNc2d1p8EMnmSTyKUCr7H1PSvpYyKrNKmPs+TtJPIrz69SEZ3TuZyhJ+hzutXrwPKptyFB+9nqK5/VTJs3QjehGVYd/au71Cxj1C2JibII59RXFeV9gnltroFLdjjcOSD2NVRr06mi3OarSnDV7HMyXYMg8yPp1PcVX/tAg4A4zwas6xZyQ3DArtP3h6MPUVjyAKRt5H8q6lGMtTn5pIvJeM7Y2/MOT7Vat70FwSenvWQGIZX6NTgynJwN2c47YpuEWHMzrrDUd0YiJ+R/0NbNld+Rco0pyjfKcehriLS5Cr8wAJ6DPSuo0qNpLbz7s+XAvRj1Y9sVyVIqGptBuWh0s0KKjMr7oD90q3J9qY7SsreYAqEY35rB/tGKJjjIQHIU9jUF/4hypQAAdASK4p0ZTeiOqFWMVqWr23t7iMxXAjnhPWORRisWTwpoEoIOk2hz3AP8AjVWTViXzwcdKdHqrZXbj/wCvWqoTjszP24y48CeHpRj+z/KPqjYqhJ8MdAkGVe9Q+iuK3/t8wxnbgjPzHFO+3y8cKfoaP3q2kWqxyr/CzSSTsubsfUj/AAqIfCazmmSKC/kDuQqhh3Nda2qlCdw5NavhW4N9qyrtxGiNlh1U9sUOdaKu5FRqpuxw138IbCwmaCS/nupFHLwjaufTmoJfgtJe2M91pGpIPs4BlhnQ7gD3BFel30d9FcOsWyRc/eBzmrWlm8VLiSchFEbfKDy/HTFN1aijdTCNR8+qPBZ/hbq6rmCaCYHpjjP51Rk+HHiRWwLRG+ki17NHfx4AJCj+VTC8iYn5uKr6xWW4/apnhjfD/wASL1sPykX/ABqCTwVr6MAdPkJPoQa9/juYuobH0FTJOMO0bnhc9aPrdVdENTR83yeGdZjjVjp1ydzbQFjJOfoKsr4M18pu/sycezDB/Kvpvw1qDwXs11HG08kEeQpPrxn3xVC4uUuJTLJNKzE7i241cMVVk9iZVIxR8u3mmX1lIY7u0uIWHZ4yKqEY619dXbW+paKFniSea1O4TSDPyf3TXOz6Bo9ySZNOtCfURgULGtO0ol80WrnzNRX0VP4K8OzH5rFR/unFUpfhv4ZkIIt51PtOatY2HVMLo8Cor3ST4YaEwPlrOnPeU1NYfB/R5YJrq5upEhiO0RB/mkPt7e9WsZTfcLo8For3+T4Y+HGjxHaXIOPv/aCf0rP1n4IxWccM8GrSNBOMp+6ztPoeaf1umnZ6CjJSu10PEKK9Sm+ElwM+VqCv6ZTH9azZvhXrq/6prZ/rJiqWJpPqO6PP6K7dvhl4iA5ith/22FQt8OtfVsGO3/7+ir9tDuHMjjqK7eL4Y+JJYzIkFuYQcGTzRtB+tOm+GHiNEJijtbhgMiOCYMx+go9tDuF0cNRW5N4T1+F2WXSL1GU4IMRyKoXel31nHvurSaJM4y6ECqU4vZjKVFFFUAUUUUAFFKOa9l8BfDC2OjpqniX52uUDW9sh5VT/ABMff0rOpUVNXYm7HjXXpVm30+8uCBBazyH/AGUJr6OsfCHh+0IaHRrZ3HRpFziuigEsUPl26RwoP4VXisJYnsjP2q6I+bLPwJ4mvMGDSLgqe5wAP1rrdN+D1/IqPqOo21uD96MZLD+le0eTI3LyHn04pDbRKBuJb6mueeKm9E7fIfO+xwGm/B3QfNiE+p3krbhldqgEV6FFommaLFHZaDCtrbJ98LyWb1JPNFt5Uc6BQCxbAA6k+laV9AiykFWVh1X0NYSqSbTk2P44tFjTJYmt5rW7PnRSDv1B9RVVEmhkeNeecD/aHrTbQhGG1fzqC61aOzuSh5JG7I9Ky5HKV47hzqMUpbGtphaG8QSI0SNx5h5A+vtV3VPD9prFu4gRXuB82BwCPxrnv+EliH8eMeopV8V+S/m27w+Z6yJnNZypVG00rM2hWppNN3Rj+J/D8kUUaRssojGME4YD/wCtXBX1rJAxXYQDXpN94lh1glNVtYonHEdzAMkfUCuS1JWhcqMXMR53IMECvSoVZrSe5wVoQveGxyUhJYZHP6U5AW+VM7+gUDJNac1msj5gx5TdWY420isLWUpp/wB8jaZSOSfb0rs9pfY5+XuTWkENpEj3/wA9wDkQDt7samvNanuSu9xtQYUDoKyrm1ZCyrJkj75z1NVG3xnPJHUVHIpO7KvbRGnLdF/vHJqrPKCCOvNVjJleT9ahL9+3QVSihXLYnAjK7VYsQdx6rjt+NXtPMDTKJG4FYe7k9fcA01HfcQuR6UOF1Yadmd/cWkEseYHUn61BHYIFzK4UDrzXGLdSr92Rhj3p73MwjXdKzZ6jNYewklbmNOdXvY6LU/s0TDy33VqeBr+0ttTmW9n8iAxtIrjqzr91foa4UTMRgk4ParEM3lhixLHOOvbvVey93leoubW6PVn1S0kYt5qBjzjNLLqtjFa3HlXEfmFCEVudx9K8lku5Nw2uevc1LBduq7t+WrmWCitbm31iR1dhZSvE0giyc5OfWklMiMRsGR7VkW/iCa3UhCp+ozVj/hIn6tGrH1xVunUvqrkXhbQvGGcoW8s4qp9pljcclagn16eVNo4B/IVmz3LSMCT7E5q4U39pEykvsnovgiZAt1KjEyKAGZumM/yrQnsLeSRnMKhicnB615rpmr3GmtK0DDbKAroejAdM/Q1pJ4puyvXnoOKxq4epzXgzSFWHKlNXO21JEg8PzRxyR2wByoPWQ+g965qN3C5MmM1SGsPdbUvZN8Ybeq9t3r9a1jPYTxrtkCtjkVPI4K0lcHJTd1oVmkdDxID3pv2yRDgnmplNih/eShgOwNVdQu7IrthTacfWhK7tYWyvckGpOCNx4611OlxC+0MSSt5Upy6MPXpivPWnTgrlg3qa7Dw/rdsNGjtJXCzRt85bkv8AQ9qupTcY80FqKnJN2lsSGxv1mxuBTPUelX9aYWWiwp5pmdpBgegqB9Ys0GXk59AKhvr0albxR2QbySd0itzhh0xWSnOfxqyNOWEb8juzP+2yY5UkelP+3ADJ61E8cqOPlz2IqNrOVxljtFU1DqZpz2LP9oj160v29CpJ28e1c9ckJIVU9KW3uEAbeWByCCD6GtVQi1ch1GjuL4+XpVpDt32oHmDb2ZuTms2CeFLhHRNjqwKsuetdEVK20BkZVMsYcbWyCp6Z/wAKom1VX3KIlIPBxWaqRj7skaOnKTumJ4j1J7+WC5uECSuu1iONwHQ1lwxWl9DNa39vHNayqUeNhwR9eoqTxSypPbxu7iXbuJbptPQj1FULW4SJ0G7Kk4yaXs0oKysPnbndu54X8T9CtvD/AIturWwUpZt88SH+FT2rkq9J+Oi48UWbnrJaK3/jxrzavRotummzqQUUUVqBJb/6+P8A3h/OvrDTpUGlWSk5CwqK+ToTiVD6MK+l9OuGXT7EnkPbqwrnrx5rGNaVkbM2pRx/LgAiqcuskcJjGOorNvX3JuB5rNklIAOcfSlCjFq9jinUknua0urys3D4FQm/kbO5yTWQZME9cmmeaA3U1bpJbIjmbN+ymaSZAZdrDkEnoa6RryYRx+YxYjO5+u7NefiZgPvYz6VIbyZRt8xgPrWNShzmlOpy7HeG+QIOQuerOcACub1a8i86TZIHXjJArCe4eQFWkZm7VHHLh/n6HggVNPDqGpc6rkrFua5xVdrj0OR3FRyThsqwGB0x1quNxViO3PNb8qRncuLOVB2kjuKRLhgSdzY9uKpSy/d2rt45x3pnmE4y20UuULmnIzysCQHTHTpioQnJMTEt6d6r+Yy7c8Gp4gzHenUcnFK1ht3KZ3buTknmpoVVg24c44xzVqeJbi3a4jIEiDLKf4h6j3qrE/BAPXvVp3JehDdQKy5QY45qg6FWweFrXcHAyCuPbrVK6VduRjIouMquyDbsPrn6VAHz908jvQTn1+tQnk46c81aAmMgHtxjpRvUBf1qIZPQ0jZJ9P6UAWWf7pHpxRkBevOeR61CSeDjP1pPmwDyRmlYZKSC3cCnjGAMiq53bchjj3pCxTjOTSGWFIGeakVwR1OaqbzkdBmnh9wLYwOnFOwi4gVs5faByPc1O7xtGBsw/qDms8PgBTUiN/n1pWAnB7gcelPV+gboDmqu4k+/alZ+gHAPAJ7U7CuXC/PXg9Kb5jYzu+lVlfAyT/8AqpfMGQOnvSsIsK59Tn1pwdsDr+NQyPEGUQmTb3LEcmns5X736UWvqBIXwg5J9qaJCRlieOmO1Ru3AYYxQSB04PrTSEW4nOMl+pwoY/qaufb7m3jys2OcKF7+9ZqSqCjcfKMEEdaVpEZy3H+yvpScU9wvY0H1u92YM3U+lNfUribJMzH1OcVlu4ZsE4xTxgg5IwOtJU4rZD5m+pYa4JHJJNPW524OfbHrVcjHPHI4NNOMZJ6Hp61fKibmvba3dWwWOOVniHO1ucfSp/7cuZUZGkOWOFPZTWGhHQ9P5U9chck5WlyR3sPmZrQXL3Msf2iZicY3SHOB6D/Cp2mAuIkDFhvHUckVmWxBADA5xkCrULZuw5Jwi5B9DWVRamsHocT8bwf7e0zeck2K5/76avN69E+NjFvENiOgWzUAenJrzutKPwI747BRRRWoxa+htBuRc+EtAuOd32YRMR6ivnivY/hjqP2vwl9hJJktJmfP+y2AKmSuc+IXu3OtnZWhLKOaype3GfQVood8UgyPlNZs52scZznmlR7HDV3TK8hIYg5BB5FN3Dkk89uKWQ5JzUTEA+9atGdyYPwMcYpPMPfv61FuwM00k454xzU2GmTEsPmAPHcdqaWODkc+tAzzgnHcetNY/LjBxzUFCO/HUVG7E8knA7+lHOOnPrTXViOvB5pMpAD27kU4hQhweR696Ztz36d6kIXIPJHvUt2GkG8ZUdTV6wuVh3/KCxHGRxVBVRB6seh9KlRc4K/xZ5+lQ2XYt28264wV+VgTgD2qnHgfK2M1Yto2Ebynt8tRS8LkfnQnqJrQfNO0sZDMXccA+grOuXAXaMFu9Pdn2gZwB+lVnViTzxiqugsQHrxUR+bp+VWCAB0/+vTVjyT7elNSCxCBweMY65pWJODnPvU+w7gMgnsKQx8+nPSjmCxCeu0dqVflHXAz+FSqh3H5QfrTWjYAcUXHYZgYJ5PrSsA2CAePanbSOmQAKVVbH9aLhYYEyCQOO4oZduQTgVMEwduQc/pS7dp59KLhYh6dP1FOGRgg/hUjxukSuVxHIcA/TrTIwAwLAlQeRTTFYcpJXk4x2p5Cldvf+VMUYAJ78CnEkMUPHqaLisOAGBjtUbDAPQ5qZVzgCiRcSH0zii4iIegHFPyWA9OwFJ1b0/rT1/WhMLCspUgEq3GeD0qMkk9zUoT+fWlMeTlTVXFYYMgDB79Kdngg08R4JHelIOAO9O4iA/e4/WnjJ5wKVk75yR2p4TAPTGKBAXyvJPA49qYT+VSldoG5eSOKjbHH6UxC7h06CpY3AiwRlSc/jUQXg+3NNznbjIzQCNC2LFUcuCc4HPIq5afPM4b7p6+9UrNcFiQCRxVzTQTdS5HTHNc89zohscJ8aG3eKYhjAW3UY9OTXn9d38ZwU8b3MLdYlVT+Wa4StKP8NHoIKKKK1AK9D+EMmLrVIsnLxoQPoSa88rrPhlfxWHiuFp2Kxyo8X1LDA/Wk9jOqrwZ6vbEi4uFJOGGRVW75kAHHvU8En78qcg8oTTb4YI2j86iLtM86avEouMZ5/wDr0zZxwDjtUhHPAz7VLFBM/EKsa2bSMkipJhkGOO/vSEAc44xV9tPmAJwvr15pWsJY0DsvB5rJzXctRZTHuMU7uOMVIU2nJH4ZpMZU56DpUuQ1Ej5ww4GfSmLAS3AyT2xViPG8Yx9K3NCiSW7ijAG5yOce/NZzqcquaRjd2MiHTM/60k9ysSlj+lXDoL/a1t4S7TN90FSAeM4z9K7++MFm5CiOEHnCLgmjTbiCaXakyhsHbv4PpwfWvPeJqPW2h2KjBaN6nls9s8LsrouQcGlgXzH46AelaOt2ckeq3EC5IRto78VZ0y02yLuXvWs6yUbmaptysZV0rW8ZjBO7HJIqhk5Oc+xrrdRsmkfIXJ96zTp8hBJi5z61nTxKa1KnQaZgnvxzURB3EMOvpXQizbn90B9KiazIJ/dHFbqvFmbptHPhMt1xgfnWjoeky6tcyQQMsYC7nlZSQo/qat/YwOqHH0rrvB0S22k3UzgQxBvvsOWPoKVSvyxvHUcKbbsznD4ZaGEGS3lLEfeDZrLvtFltrUXRDG18wRb2UjDHoP8A69eiR6patNgSOp9SOKTxoEOjRqzq0TEKuw/KSeenrWEK9VSSmtzWVOm4txex5pBbGR8FwPr0q6dNWIASbTnnNKtqU+7zntU6qdoDA/zreU9dGYpaaohXS458eWyq54wao32kzWxwcEe1aYQ7iQzD8Kjn8zAwScD86IzlfRjaVtjHSBum0lunAqRrSYJu8v8AAcmvRfDOnQDQUkuYw0rsW3d8elXLrSrK4iMaAwuRxIh6GsZ41Rly2NYYZyje55X5JKDccY7f56VOlmcggEA+1dT4v05LW6tmt0CqsCI4H/LVh1c+hPpVC0YQW+8vG2442Z5Fb+1bjzRMeS0uWRkHTnY/KM1HNbMsIEkZ3Jn5sfeH/wBatpiwJI4BNaFvqUKwslzbLIDxn0pOrJK6VxqEW7PQ5BUIAxjPrStEeM9/WtS6WN5SY4ztz0Brch8G3TRW0zzQlJYxIqrJ90Hsff2q5V4wXNLQiNJydo6nIC3LZwRj0p6QfLxjI6iuuufDFztAjgDMTgGNsn8RVG807+zNQlsZ5IZXiPMkJ3K30NOGIjNXiEqTh8Rg+UeM/nTSpHX+VdGkERHIBz2pUtbaXhwUJ4zT9ukT7M5tlOef0o29fX1revNHCKWilDJ7VnNAVBB4ArSNWMloRKDjuUfL6nGc0hU7SOw61px27TElEwT3PAND2ThecH1xVKothcrM7LAhmwSfXvQ6FWBA6jI+laa2ErICF6+3alGnSEAA8g55/lT9pEXKzI69c0qBBncDWlPpsyZITIPORVdYH5yMGqU09mLlfUltV+VsdKv6TC0lzIp53MvNQWsJEbZrW8PhV1KN3BKK4Jx6AGuWpK12dEFoeN/Fi5F38Q9blX7pmwPwUCuRq/rtyb3Wb24brJKx/WqFddOPLBLyO4KKKKsAqxYS/Z723m/55yK/5HNV6KAPoNbYo6uTkSIsob/eGalvYhtyByaoeBdRbXfCNk8jA3NoTBIR/d/h/QVtXce6PnkAd64+ZqVn0OCUbXRl28QdwpbC+tdfpOi28mmwzSCTaST5fY/U1yoRsHb2Fdg1/LHpFrbRqRGy5Zx3PpTrtyVosilZO8kW20uzuEMb26BSMZDcis7xZttbaC3jjRYSoVG7jHXP1qGHcnzgvu65q3r1hd6jaWMtxEVbkRnGN49cVzcns2nJ6Gyn7RWS1OGaNmY4wRnrUi2bkBhknvXTLopiX9/+6X1YYFMuZdD06Pff6zZoB/Cjhm/IUSxaekQjQZz6WDHpxWlp8MltcwvzgMDkDpWDqvxM8Nae7Lp9vcaiehY5iH61h3HxiuEydP0q3jJ6ed84pWr1No/fobxoxW7PV9SsruC5Jukwr/vFcnIYGpdH0iTUb6KLeI1J/wBYRwPyrxZPjL4jcMl5FYTwEYCGDG36c1Dqnxe8SXVm1tZNb6ejLtMltHtkI9N1P2GIas7FeyhzX6Hq/i7WPDOn67dW9zrkAe1PlMFBYuR1ORXHX3xM0CxfZp9pdXJHIfICk/jzXixdjkk8nkmmVrHL4L4m2a83ZHrMvxbWSQbtJXYO4b5qki+KlgSfM0+6XPdWXivIqK0+o0VshOTe57TbfErR5Dh0uoh6tg/yrSt/HOgSjnUViJ/56If6CvBKKl4Cl0FqfQsXivQZWULqtqx91I/pXQ6BqujarDJYSanbI6DfbruADn05718s0VH1BL4ZND9T6vTSo5LvYHjxjO/cNv51J4ktbCxtYLKPUba7d2E7qkqnyiOMda+XY9a1OO0a1S+uFt2G0xhzgiqCsynKkg+xoeDm95/gRGEV0PpQWsTfd5H+ywNPayVwAVbjpxXztbazqNt/x73txH/uuRV+Hxhr8P3dUuCPds1DwNTpIdke7nTk65YfUVDJYrsbbJjg9q8cg+IXiOHGL3cB2Zc1eh+KGvxjDizkHfdDz/Oo+qV1s0HLFnvBjuY9BtIrME2+OZQOrelUrUXkNwHRnYg/dYZB+tea6P8AGzUrW1azvNPtZbMtv2xDYwP1q7a/GqC1uTPDormXO4b58jP0xUqjXimuQJU4tp3Z33iqKa8ltjIojk2ksh45Peuf/s6QH7gz9a5LUvjA+qX8t3faXvlk/uyYAA6AcVEnxQss/PpE31E//wBalGjiIq3L/X3hKEW7nZ/YZgvCc+xp32SZWDbCMdK5m2+JejOQJ7e6iU9cHditSDx94YfrqFzH6BoGpONZbxf3E+zTLps3DqTGx+YH6813eoX8NokcQDSOqgFEx8vsa4eLxl4dmxs1cDHTdCRXZy3/AIc1eytrzQ76CaRkC3Me8Blk7nb6e9ZyfM17SLGouCfIxdN1WJ5wJPMgPYt0J9K53xNGia1Kqx7XHX3rf06HTJCZdTu4LWFASRJKFJx6Z61kXN7a307Sm4tTnhQJQSB2oUoQleCJcZzh77MZH9Vzig4PIBBrVEducBSjY/uvmpBZo5yImbHcVo6xn7MxSp42sfpU2j2LXerW8ZbGG3Z+lao08YOYJBn2NWNMto7bUYJNrEhhgdM+1V7fSyF7PW7OkuEjjd3SOKMvjPAGfzqKzsrX+0oL/wCzQyTWzeYit9xnHTdjtWLrNpdXV25umbepwUJwF9qs+HYby1uiYQzw4/eKxyuPWs1RUVzqWpr7ZyfLy6HO3Usp1K5mkKrI8rMwXoCSTx7U2cmVtwYE47VYurPNxI0TgIXJAJyevrUDWcvUba6FOL1OZxa0Etbl7cEcMnUg1T1B0nmLogXHIxVl7ebbgDNRm3kH/LOri1fmFrawy1i4we/NQaxI2n+G9VuUJEqWzlT75GK0rRX37WQjPArO+KO208C3cjYDSusCqepyP/rVDleaXc2pxuj57ZizFj1JzSUUV6h0BRRRQAUUUUAeh/BvxDY6TrU1nq8ogs7xcCUn5UkH3S3t1r2qaC3ugslvLFMnqjjB96+UqkE8o4ErgezGuepQ55cydiJQ5j6faXSbTP27VLC1K9RI/NRXnxO8K6Npj2Au11KMnINugJX6E18xs7t95mP1NNrN4NS+N3CEOXY96ufi14egt5HsrS8uJsHZFMoVfoSDmuL8R/F7xNrEMdtFMlnZxKVjijGSoP8AtHmvOaK1jhqcelylFIvz6xqVwT52oXb56hpmI/nVFmLMSxJJ6k0lFbJJbDCiiimAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUkM0sLboZHjb1RiDUdFAE01zPOAJ55ZAOm9yf501ZpV+7I4+jGo6KLAWFvbpfu3M6/SQ1Kuqagv3b67H0mb/GqVFKyA1bfxDq9uwaPUrrI9ZWP861bfx94jgOY9QbPugNcrRUunB7oLHp0fxj12WMDU4be9kxgufkJ+uKSf4x6+bZre1jgt4HxvVeSQO2a8yorP6tS/lDrc9Cj+KerAYkt7d/0qxH8Vrsf6zS7d/+2rCvNaKf1en2J5UetW3xVtmH+k6Vs6Y8uUn+dXF+KGjsvz2t0D6DH+NeM0VP1amL2aPb4finoUcbu1rdtKo+RCBgntk5rzrx14zvPFtzA00S21vApEcEbEgZOSST1NcrRThh4QlzLcpKysLSUUVuMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Studded silicone Hood tracheobronchial stent with cut-off for right main bronchus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_30_28142=[""].join("\n");
var outline_f27_30_28142=null;
var title_f27_30_28143="Occiput anterior position";
var content_f27_30_28143=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Occiput anterior positions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 159px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     A: Right occiput anterior (ROA); B: Left occiput anterior (LOA); C: Occiput anterior (OA).",
"     <br>",
"      * Posterior fontanel. This is the smaller of the two fontanels and is at the intersection of the three sutures: the sagittal suture and two lambdoid sutures.",
"      <br>",
"       ** Anterior fontanel. This large fontanel is at the intersection of four sutures: the sagittal, frontal, and two coronal sutures.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_30_28143=[""].join("\n");
var outline_f27_30_28143=null;
